Wright State University

CORE Scholar
Browse all Theses and Dissertations

Theses and Dissertations

2007

Differential effects of mutant TAp63γ
TAp63 on transactivation of p53
and/or p63 responsive genes and their effects on global gene
expression
Shama Khan Khokhar
Wright State University

Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all
Part of the Molecular Biology Commons

Repository Citation
Khokhar, Shama Khan, "Differential effects of mutant TAp63γ on transactivation of p53 and/or p63
responsive genes and their effects on global gene expression" (2007). Browse all Theses and
Dissertations. 207.
https://corescholar.libraries.wright.edu/etd_all/207

This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE
Scholar. For more information, please contact library-corescholar@wright.edu.

Differential effects of mutant TAp63γ on transactivation of p53 and/or p63 responsive
genes and their effects on global gene expression.

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

By

Shama K Khokhar

M.Sc., Bilaspur University, 2004
B.Sc., Bhopal University, 2002

2007

1

COPYRIGHT
SHAMA K KHOKHAR
2007

2

WRIGHT STATE UNIVERSITY
SCHOOL OF GRADUATE STUDIES

Date of Defense: 12-03-07

I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY SUPERVISION
BY SHAMA KHAN KHOKHAR ENTITLED Differential effects of mutant TAp63γ on
transactivation of p53 and/or p63 responsive genes and their effects on global gene
expression BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE DEGREE OF Master of Science

Madhavi P. Kadakia, Ph.D.
Thesis Director
Daniel Organisciak , Ph.D.
Department Chair
Committee on
Final Examination
Madhavi P. Kadakia, Ph.D.
Steven J. Berberich, Ph.D.
Michael Leffak, Ph.D.
Joseph F. Thomas, Jr., Ph.D.
Dean, School of Graduate Studies

3

Abstract
Khokhar, Shama K. M.S., Department of Biochemistry and Molecular Biology,
Wright State University, 2007
Differential effect of TAp63γ mutants on transactivation of p53 and/or p63 responsive genes and
their effects on global gene expression.
p63, a member of the p53 gene family, known to play a role in development, has more recently
also been implicated in cancer progression. Mice lacking p63 exhibit severe developmental
defects such as limb truncations, abnormal skin, and absence of hair follicles, teeth, and
mammary glands. Germline missense mutations of p63 have been shown to be responsible for
several human developmental syndromes including SHFM, EEC and ADULT syndromes and are
associated with anomalies in the development of organs of epithelial origin. The contrasting
phenotypes associated with the different classes of p63 mutations might be in part due to the
differential regulation of target genes. A previous report has demonstrated that heterozygous p63
mutations display high predisposition to tumor formation. Moreover, it has been shown that both
p63 and p73, another member of the p53 family, are required for p53 mediated DNA damage
induced apoptosis. Finally, differential splicing of p63 gene gives rise to p63 isoforms which can
either act as tumor suppressors or oncogenes. The goal of this study is to determine the effects of
naturally occurring TAp63γ mutants on regulation of p53/p63 and p63 specific target genes and
their effects on global gene expression. Our results indicate that both TAp63γ(R227Q) and
TAp63γ(R298Q) mutants mimic wildtype TAp63γ effects on its target genes. TAp63γ(K194E)
and TAp63γ(R280C) significantly induced genes regulated by p63 and p53, but not those
specific for p63. TAp63γ(R279H) and TAp63γ(R204W) were unable to induce any of the targets
tested in this study. Co-transfection of p63 mutants along with wildtype p63 was performed to
assess the effects of p63 mutants on ability of wildtype p63 to induce its target genes, while coiv

transfection of TAp63γ(R279H) and TAp63γ(R204W) led to a complete inhibition of the
wildtype TAp63γ mediated induction of p63 specific target genes, they had no effect on p53/p63
target genes. We demonstrated that the ability of these mutants to regulate wildtype activity was
independent of their ability to either interact with wildtype TAp63γ or affect its localization. In
addition, we demonstrated that the effects of these mutants on cell growth and survival were
consistent with their ability to regulate the downstream targets when compared to wildtype
TAp63γ. Furthermore, our analysis of the GeneChip data using GeneSpring led to the
identification of several common and unique genes regulated by specific p63 mutants when
compared to cells transfected with wildtype p63. Additionally, the specific genes regulated by
the p63 mutants observed in EEC, SHFM and ADULT syndrome might offer unique insights in
understanding the involvement of p63 in development, ectodermal-mesenchymal interactions
and differentiation. In summary, we show that p63 mutants exhibit a differential effect on p63
specific and p53/p63 specific target genes and on induction of apoptosis. This, in turn might have
a significant impact on p63 mutation associated abnormalities of human developmental
syndromes. Taken together, our data shows that p63 mutants differentially regulate gene
expression and provide an insight into the molecular biology of p63. Further, these results will
aid in better understanding of role of p63 mutants in development and cancer.
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I. Introduction:

1. Discovery of p63 and its structure:

p63 is a member of the p53 tumor suppressor gene family. The p63 gene is composed of 15
exons and is located on chromosome 3q27-29 (Mills et al., 1999; Yang et al., 1998). Although,
p53 was considered to be different from its other family members due to absence of different
isoforms, recent evidence supports that even p53 has many isoforms (Muller et al., 2006). p63
exhibits high sequence and structure parallel to p53 which led to early speculations that p63
would function as a back up tumor suppressor to p53 and could substitute p53 in promoting its
tumor suppressive functions through transactivation of its target genes. Like p53, p63 also serves
as a sequence specific DNA binding transcription factor that activates target genes involved in
cell cycle arrest, DNA repair and apoptosis (Osada et al., 1998; Yang et al., 1998). The p63 gene
with alternate promoter usage and differential C terminal splicing gives rise to six isoforms with
remarkably diverse activities as transcription factors. TAp63α, TAp63β and TAp63γ contain the
N terminal transactivation domain (TA), whereas the ΔNp63α, ΔNp63β and ΔNp63γ are
transcribed from an internal promoter and lack the transactivation domain (Figure 1). Both TA
and ΔNp63 isoforms have a DNA-binding domain, which is approximately 65% identical to the
DNA-binding domain of p53, and an oligomerization domain with about 35% identity to that of
p53. The TA isoforms with the transactivation domain are more closely related to p53 because
apart from the above mentioned two domains, they also have partially homologous TA domain
with 25% identity to p53. The TA isoforms are able to drive expression of the p53 target genes
due to their ability to bind to p53 responsive elements
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Figure 1: Schematic of p63 gene structure: Representation of the high sequence and structure
homology of p63 with p53 protein, in dictating the amino acid identity among the different
domains. p63 has six different variants generated due to differential promoter usage at the N
terminal and C terminal alternate splicing. The TA isoforms contain the transactivation domain
while the ΔN isoforms lack the TA domain. The TA isoforms are more similar to p53 in structure
because both of them contain the Transactivation domain (TA), DNA-binding domain and
Oligomerization domain (OD). In addition to these domains, the α-isoforms contain a sterile α
motif (SAM) domain and a transactivation inhibitory domain (TID) at their C-termini. The
percentage represents the amino acid identity between similar domains of p53 and p63 (adapted
from Bokhoven et al, 2002).
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(Westfall et al., 2003). However, the divergent outcomes of the mice knock out models of these
two genes clearly imply that they regulate distinct subsets of target genes. This can be partially
explained by the existence of a distinct p63 consensus DNA binding site, to which p63 proteins
bind preferentially (Osada et al., 2005; Perez et al., 2007) as shown in Figure 2. The ΔN isoforms
can also bind to p53 RE and exert dominant negative effects over p53, by competing for DNA
binding sites (Murray-Zmijewski et al., 2006). Reports also showed that ΔNp63 isoforms are
able to activate target genes which are not induced by TA isoforms (Dohn et al., 2001; Wu et al.,
2003). The carboxy terminal of the alpha isoform contains a SAM (sterile alpha motif) domain
which is a protein-protein interaction domain also found in other developmentally important
proteins (Ianakiev et al., 2000). SAM domain has been shown to be involved in other cellular
processes such as chromatin remodeling, focal adhesion apoptosis and receptor kinase signaling
(Loenen, 2006; Thanos and Bowie, 1999). Downstream from the SAM domain is a
transcriptional inhibitory domain (TID) that can act either in cis or trans to regulate
transcriptional activity of p63 (van Bokhoven and McKeon, 2002). Hence, six different isoforms
of p63 are present in cells, at different levels of expression (Testoni and Mantovani, 2006). The
molecular complexity of p63 is attributed to complex structure that gives rise to six different
variants which either act as transcriptional activators or repressors. The differential expression of
different p63 isoforms regulates the complex biochemical activities, implying its role during
development and carcinogenesis.

2. p63 in development:

4

p63 is expressed in basal cells of the skin, cervix, tongue, esophagus, mammary glands and
prostate. Unlike p53 knockout mice which developed spontaneous tumors, p63 knock out mouse
was found to have several developmental defects and died within a day of its birth owing to
dehydration and maternal neglect (Donehower et al., 1992; Mills et al., 1999; Yang et al., 1999).
Mice lacking p63 display severe developmental defects such as limb truncations, abnormal skin
and absence of hair follicles, teeth and mammary glands. These defects in organs of epithelial
origin demonstrated that p63 plays a pivotal role in embryonic development. The surface
epithelium of p63 null mice consists of single cell layer that fails to proliferate and differentiate
into mature epithelium (Mills et al., 1999; Yang et al., 1999). Recent studies indicate p63 as a
critical factor for molecular switch of epithelial stratification. However, role of p63 in
development and differentiation of epithelial stem cell still remains controversial and the center
of debate. While some argue that p63 is essential for proliferative potential of already committed
epithelial stem cell, but not essential for commitment of simple ectoderm to epithelial stem cell
(Yang et al., 1999), others believe that p63 is essential for both commitment and differentiation
of simple ectoderm to simple epithelial lineage (Mills et al., 1999). However recent findings
have suggested the involvement of p63 not only for commitment and differentiation of ectoderm
to simple epithelium but also for proliferative potential (Koster et al., 2007). The argument in
favor is that this dual role of p63 is due to the existence of six different variants which act in a
differential manner. To further explicate the role of p63 in epidermal development, studies were
undertaken to see the individual role of TAp63α and ΔNp63α using transgenic mice
complementation studies (Candi et al., 2006). The TAp63α complemented mouse has a similar
phenotype like p63 knock out mouse, with no epidermis. In
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Figure 2 : DNA binding sites in p53 and p63 identified by different approaches. p63 binds to
DNA binding motif with unique characteristics distinct from the p53 DNA consensus site. Osada
et al identified that p63 has higher specificity for responsive elements containing the half site 5’RRRCGTGYYY-3’. p63 specific DNA consensus site is characterized by the presence of a G in
the 5th or 6th position in the core domain and a relatively high number of mismatches in the
purine and pyrimidine rich flanking regions (adapted from Perez et al, 2007).
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sharp contrast, the ΔNp63α transgenic complemented mice had more epidermis. The ΔN
complimented animals expressed greater amounts of basal layer proteins K5 and K14 than either
the p63-/- and p63-/-; TA-/-. However, both the p63-/-; TA and p63-/-; ΔN mice died within a
few hours of birth. This study suggested that exogenous introduction of the either of the p63
isoform does not compensate for the absence of endogenous p63.

3. Role of p63 in human diseases:

Mutations in p63 have been documented in several different human developmental disorders
(Figure 3A). These p63 related disorders observed in human beings have certain phenotypic
characters similar to p63 knock out mice. Ectodermal dysplasia, Split foot/hand malformation
and craniofacial defects are the hallmark features observed in p63 mutations. Ectrodactyly,
ectodermal dysplasia and cleft-lip palate (EEC) syndrome is characterized by ectodermal
dysplasia with developmental anomalies reflecting perturbation of skin, limbs, hair, teeth &
apocrine glands. The severe defects that are associated with the EEC mutants are dependent on
the nature of the mutation (Rinne et al., 2007). The amino acids in the DNA binding domain are
very crucial for the interaction with DNA, therefore mutations of these amino acids may have an
unfavorable effect on their DNA binding, also leading to a decrease in their transactivation
ability (van Bokhoven et al., 2001). Strikingly most of the germline mutations observed in EEC
mutations have similar locations as the hot spot mutation
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Figure 3: p63 mutations associated with human developmental syndromes. A) Distribution of the
p63 mutations identified in different human developmental disorders. Mutations in EEC and
SHFM syndrome are localized to the DNA binding domain that are expected to abrogate
interaction with DNA and lower transactivation activity. RHS and AEC are localized to the SAM
domain. LMS mutations are frame shift mutations in exons 13 and 14. Abbreviations: EEC,
ectrodactyly, ectodermal dysplasia, clefting; AEC, ankyloblepharon, ectodermal dysplasia,
clefting; ADULT, acro-dermato-ungual-lacrimal-tooth; SHFM, split hand/foot malformation;
LMS, limb-mammary syndrome; RHS, Rapp Hodgkin syndrome; NSCL, Non syndromic cleft
palate (adapted from Rinne et al, 2007). B) The syndrome phenotype is determined by the
position of the mutation. Strong genotype-phenotype co-relation is seen especially in LMS, EEC
and ADULT syndrome as mutations observed in these conditions are clustered in the DNA
binding domain. Also, AEC and RHS syndrome mutations are clustered in the same domains
(SAM and TID) and give rise to very similar clinical phenotype.
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sites in p53 gene. The arginine codon mutation in p63 like R204, R279H, R304, R280
correspond to the hotspot mutations in p53 like R175, R248, R273 and R249 respectively, which
also lead to loss of DNA binding capacity (Li and Prives, 2007). Ankyloblepharon, ectodermal
dysplasia, clefting (AEC) or Hay Wells syndrome is characterized by ankyloblepharon or fused
eyelids and lack of limbs. Ectodermal dysplasia is more pronounced in AEC than in EEC.
Mutations in AEC syndrome are localized to the SAM domain so it only affects the alpha
isoforms (Figure 3). These mutations disrupt the protein-protein interaction function leading to
the loss of normal biological activity associated with this domain. Rapp-Hodgkin syndrome
(RHS) is manifested with alopecia, hypodontia and dry skin. Similar to AEC syndrome, this
syndrome lacks the orofacial clefting and limb defects. Also the mutations in RHS are point
mutations and deletion mutations in the SAM and TID domain. Limb-mammary syndrome
(LMS) is characterized by mammary gland and nipple hypoplasia, no hair and skin. Acrodermato-ungual-lacrimal-tooth syndrome (ADULT) is distinguished by neurodermitic signs,
excessive freckling and exfoliative dermatitis. Protein modeling data suggests that R298Q
mutation which resides in the DNA binding domain of p63 does not lead to the loss of the
transactivation potential. Split hand-split foot malformation (SHFM), a limb malformation is
characterized with absence of median digital rays of the hand and feet and Syndactyly of digits
(Czeizel et al., 1993). NSCL (Non-syndromic cleft lip/palate) is characterized by orofacial
clefting (Rinne et al., 2007).

Combined p63 mutation data for these syndromes indicate extensive genotype-phenotype
correlations with each of these syndromes having a distinct pattern and type of mutations (Celli
et al., 1999; Rinne et al., 2006). For example, majority of mutations observed in EEC syndrome
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are missense mutations generating amino-acid substitutions in the residues involved in DNA
binding, thereby affecting all p63 isoforms (Kantaputra et al., 2003; Ying et al., 2005) . On the
other hand, mutations causing AEC and RHS syndrome are all missense mutations coding for the
SAM domains, thus only p63α isoforms are affected (Figure 3B). It is interesting to note that
EEC mutations, and not AEC mutations, cause limb defects. Similarly LMS mutations cause
mammary gland dysplasia but mutations in EEC or SHFM rarely do. The differences in part
could be due to different sets of genes regulated by p63 and p63 mutants. Mutations in p63 could
lead to loss of function or gain of function which results from a combination of specific proteinprotein interactions as well as activation or repression of specific target genes. Since, p63 is a
transcription factor, the molecular targets of p63, both normal and specific to p63 mutants will
provide insight on the mechanisms underlying its role in development.

4. p63 in cancer:

The role of p63 in tumorigenesis still remains unclear and controversial. Even though p63
mutations are rarely detected in human cancers, several studies have implicated that p63 might
play a role in cancer progression. Loss of p63 and p73 has been associated with aggressive tumor
progression and poor prognosis (Koga et al., 2003; Park et al., 2000; *Urist et al., 2002; Urist et
al., 2002; Wang et al., 2002). In addition, loss of p63 expression has also been correlated with
cancer progression in various cancers including prostate and bladder cancers (Park et al., 2004;
Parsons et al., 2001; Urist et al., 2002).

12

TAp63 isoforms have been shown to promote growth arrest by inducing anti proliferative genes
like Insulin Growth Factor Binding Protein-3 (IGFBP-3), BAX, Vitamin D receptor (VDR) and
Maspin (Kommagani et al., 2006; Senoo et al., 2002; Shimada et al., 1999; Spiesbach et al.,
2005; Wu et al., 2005), and inhibiting the pro proliferative genes like Vascular Endothelial
Growth Factor (VEGF) & Heat Shock protein 70 (HSP70) (Senoo et al., 2002; Wu et al., 2005).
Although loss of p63 co-operates with loss of p53 in tumor development, the exact mechanism
for this action is still unclear (Flores et al., 2005). Several studies have suggested the possible
role for p63 in several different apoptotic pathways. TAp63α protein has been shown to induce
apoptosis by activating both mitochondrial and death receptor apoptotic pathways which
sensitizes the cancer cells towards chemotherapy (Gressner et al., 2005b). Endogenous p63 has
been shown to be induced by many chemotherapeutic agents and blocking this function by p63
mutants might confer chemoresistance (Petitjean et al., 2005). In addition, TAp63 isoforms have
been shown to be critical for mitochondrial apoptotic pathway upon NGF withdrawal in
developing sympathetic neurons (Jacobs et al., 2005). Further, TAp63 isoforms were shown to
accumulate upon DNA damage induced by Topoisomerase II inhibitors (Katoh et al., 2000;
Okada et al., 2002; Petitjean et al., 2005). The role of p63 in tumorigenesis has been supported
by studies using p63 involving heterozygous mice which were predisposed to tumor formation
and displayed loss of heterozygosity (LOH) for the wildtype allele (Flores et al., 2005). In
contrast, various reports refuted the LOH for p63 in heterozygous mice, and argued against the
notion that p63 might act as a tumor suppressor (Keyes et al., 2006; Koster et al., 2006).
However, TAp63 isoforms have been shown to promote apoptosis during embryonic
development possibly by coordinating with other counterparts of the p53 family (Flores et al.,
2002; Jacobs et al., 2005). In contrast, ΔNp63α isoform, that lacks the TA domain represses the
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expression of IGFBP-3 and induces expression of HSP70 and VEGF to promote proliferation in
squamous carcinomas. Several studies indicate the role of ΔNp63α as an oncogene since, it is
over expressed in various cancer types and has been shown to induce the pro survival proteins
(Casciano et al., 2002; Choi et al., 2002; Hu et al., 2002; Park et al., 2000; Senoo et al., 2002;
Sniezek et al., 2004; Wu et al., 2005). ΔNp63α has also been shown to repress p21 and 14-3-3σ
genes, thereby inhibiting the p53 mediated growth arrest and apoptosis (Westfall et al., 2003).
Additionally, ΔNp63α isoform act in a dominant negative manner towards p53 and TAp63
isoforms by inhibiting their target genes, to maintain the proliferative potential of epithelial stem
cells. Together, all these studies point towards the relevance of studying the biological effects of
p63 mutants. Even though the role of p63 in tumorigenesis remains unclear, general consensus is
that ΔNp63α promotes proliferation hence acting as an oncogene, whereas TA isoforms
promotes cell cycle arrest and apoptosis thereby performing tumor suppressive functions.
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5. Rationale:

Since the discovery of p63 as a p53 family member, it has been investigated as a back up tumor
suppressor gene. The importance of p63 was demonstrated by the p63 knock out studies where it
was shown to play an important role in development. p63 can induce cell cycle arrest and
apoptosis by activating p53 specific target genes. Loss of p63 and p73, another member of p53
family, results in failure of cells with functional p53 to undergo apoptosis in response to DNA
damage (Flores et al., 2002). Due to sequence and structure homology in the oligomerization
domain of p53 and p63, like p53, p63 also functions as a tetramer. Also, the human
developmental syndromes associated with p63 mutations indicate genotype-phenotype
correlations with each syndrome having a distinct pattern and type of mutation. However, little is
known about the precise pathogenetic mechanism that underlies the phenotypic specificity
observed in different mutational classes. In this dissertation research we tried to address two
specific aims. Firstly, we investigated the effect of naturally occurring TAp63γ mutants on
biological activity of wildtype TAp63γ. We chose TAp63γ as it has been shown to be the most
potent transactivator of all other p63 isoforms (Shimada et al., 1999). Also, the mutations that we
included in our studies are germline mutations localized in the DNA binding domain which are
common to all isoforms of p63. Our hypothesis was that p63 mutants interact with wildtype p63,
abolishing its DNA binding capacity and disrupting its activity. Thus, the binding of p63 mutants
to wildtype p63 can lead to inhibition of its transcriptional activity which might potentially result
in a subsequent loss of its biological functions like growth arrest, apoptosis and differentiation.
Therefore, these p63 mutations can gain additional functions by regulating wildtype p63 function
and thus actively contribute to cancer and development. Secondly, we performed gene
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expression studies, to identify novel target genes regulated by these mutations. We hypothesized
that the distinct phenotype observed in human developmental syndromes associated with specific
p63 mutations is due to differences in the target genes regulated by these mutants. In this aim we
investigated the differential regulation of target genes by each of the p63 mutants by analyzing
the gene expression profile using DNA microarray following overexpression of these mutants in
a mammalian cell line.
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II. Materials and Methods:

1. Cell lines and plasmids: H1299, a human non-small lung carcinoma cell line (obtained
from ATCC) and HCT 116 p53-/-, a colon epithelial cell line (a generous gift from Dr
Steven Berberich, Wright State University) which are devoid of p53 were maintained in
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% Fetal Bovine calf
Serum (FBS) and 1% PS (Penicillin and Streptomycin) at 37oC, in a humidified 5% CO2.
Expression plasmids encoding GST-TAp63γ and HA-TAp63γ were constructed by
cloning the coding sequence of TAp63γ (p51A), into pcDNA3.1myc and pcDNA3.1GST
(Invitrogen) (Kadakia et al., 2001). The p51A cDNA was a kind gift from Shuntaro
Ikawa (Tohuku University, Japan). GST tagged TAp63γ mutants were created using PCR
based site-directed mutagenesis method using sense and antisense primers. The primer
sets

for

the

mutants

included

in

this

study

(5’GGAGGGATGAACCACCGTCCAATTTTAATC3’)
AAATTGACGGTGGTTCATCCCTCC3’)

2)

are
and

K194E

1)

R279H

antisense

sense

sense

(5’GATTA-

(5’CATGCCTGT-

CTACAAAGAAGCTGAGCACGTCAC3’) and antisense (5’GTGACGTGCTCAGCTTCTTTGTAGACAGGCATG3’)
TGGTGCCCCAACCATG3’)
CTTCACCACCTCC3’)

4)

3)

and
R227Q

R204W
antisense
sense

sense

(5’GGAGGTGGTGAAG-

(5’CATGGTTGGGGCACCA-

(5’CTCCTAGTCATTTGATTCAAG-

TAGAGGGGAACAGC3’) and antisense (5’GCTGTTCCCCTCTACTTGAATCAAATGACTAGGAG3’) 5) R280C sense (5’GGAGGGATGAACCGCTGTCCAATTTTAATCATTGTTACT3’)

and

antisense

(5’AGTAACAATGATTAAAATTGGACA-

GCGGTTCATCCCTCC3’) 6) C306R sense (5’GGCCCGGATCCGTGCTTGCCCAG3’)
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and antisense (5’CTGGGCAAGCACGGATCCGGGCC3’) 7) R298Q sense (5’GCAAGTCCTGGGCCAACGCTGCTTTGAGG3’) and antisense (5’CCTCAAAGCAGCGTTGGCCCAGGACTTGC3’). PG13-Luc reporter plasmid containing 13 copies of p53
binding DNA consensus sequence was obtained from Dr. Steven Berberich (Wright State
University, USA). Other reporters, Maspin-Luc and Hdm2-Luc were kind gifts from Dr
Lindsey Mayo (Indiana University, USA). Shh full length promoter construct was
constructed as reported earlier (Caserta et al., 2006). Membrane bound hybrid GFP
plasmid, PAB35 was a kind gift from Dr Lynn Enquist (Princeton University, USA).

2. Transactivation studies: : To measure the PG13-Luc, Hdm2-Luc, Maspin-Luc and ShhLuc reporter activities, cells were seeded in 24-well plates at 5 x 104 cells/well (for
H1299) and 1 x 105 cells/well (for HCT p53-/-). At 24 hr after seeding, cells were
transfected with 100 ng of reporter constructs and a constant amount of CMV-Renilla
Luc plasmid, along with desired plasmids as indicated using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). All transfections were done in duplicate. After 5 hr
incubation the medium was replaced with DMEM medium supplemented with 10% FBS
and 1% PS. At 24 hr post transfection, cells were washed once with 1X PBS and whole
cell extracts were made by adding 100 μL of Passive Lysis buffer (Promega, Madison,
WI) directly onto the plate and put on a rocker at room temperature for 30 min. The
lysates were then transferred into 1.7 mL eppendorf tubes. Dual luciferase assay was
performed to detect both firefly and Renilla luciferase activity using Dual-Luciferase
Reporter 1000 Assay System as per manufacturer’s protocol (Promega, Madison, WI).
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Briefly, to measure reporter activity 2 μL of each sample was taken in separate tube and
50 μL of LASII reagent was added to the tube and mixed well by pipetting and
immediately placed in a luminometer to get the reading for firefly luciferase. This was
followed by addition of 50 μL of Stop and Glow reagent to the same tube and vortexing,
to allow proper mixing, the sample was read again to get the Renilla luciferase reading.
The relative luciferase activity was measured by calculating ratio of Firefly luciferase
activity to Renilla luciferase activity. The average of the ratios from duplicate samples
was then plotted in a graph where error bars represented standard deviations.

3. Protein Isolation and Immunoblotting studies: H1299 and HCT116 p53-/- cells were
seeded onto 6 well plates with 2.5 x 105 cells/well and 5 x 105 cells/well respectively. At
24 hr post seeding, cells were transiently transfected with desired plasmids using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA), in serum and antibiotic free DMEM.
After 5 hrs incubation the medium was replaced with DMEM medium supplemented with
10% FBS and 1% PS. At 24 hr post-transfection, cells were first washed with 1X PBS
and harvested in Radio Immunoprecipitation Assay (RIPA) buffer (0.5% sodium
deoxycholate, 1% NP-40, 0.1% SDS, phosphate buffered saline, pH 7.4). The buffer with
1% protease inhibitor cocktail (Sigma) was added onto the plates directly and placed on
ice for 30 min. The cells were then scraped and transferred to 1.7 mL eppendorf tubes.
The extracts were placed for an additional 30 min on ice, to allow complete lysis of the
cells. The samples were then centrifuged for 5 min at 14,000 rpm at 4oC. Protein
concentration was determined using BCA reagent (Pierce, Rockford, IL), using a 96 well
plate. Standard curve was generated using bovine serum albumin (BSA) ranging from 1
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μg/μL to 13 μg/μL. For each of the sample 2μL of sample and 98 μL of sterile distilled
water were mixed properly and 100 μL of BCA reagent added to each well and incubated
at 37oC for 15 min. The absorbance was measured using a spectrophotometer at the
wavelength of 562 nm and the protein concentration calculated using a standard curve.
Equal amount of protein was used from all samples and mixed with 5X SDS loading dye
(0.5 M DTT, 0.3 M Tris (pH 6.8), 10% SDS, 50% glycerol and 0.05% bromophenol blue)
and heated at 97oC for 5 min prior to loading. Protein extracts were run on 10% SDSPAGE gel using 1X SDS buffer (25 mM Tris pH 8.3, 250 mM glycine, 0.1% SDS) for
about 4 hr at 200 constant volts and transferred onto PVDF membrane (Millipore
Corporation, Billerica, MA) using transfer buffer (25 mM Tris, 192 mM glycine, 20%
methanol and pH 8.3) at 1.10 Amps for 1 hr using a Transblot system (Bio-Rad) and
blocked with 5% blocking milk solution (1M Tris pH 7.4, 5M NaCl, 0.05% Tween-20
and 5% non fat dry milk). The membrane was then subjected to immunoblotting at room
temperature (in 5% non fat dry milk made in 1X TTBS (Tris-Tween 20 Buffered Saline)
using antibodies to detect specific proteins overnight. Mouse monoclonal anti-VDR D-6
(1:2000), rabbit polyclonal anti-p21 C-19 (1:2000), rabbit polyclonal anti-Shh H160
(1:250), mouse monoclonal anti-p63 4A4 (1:4000) (Santa Cruz Biotechnology, Santa
Cruz, CA), mouse monoclonal anti-Mdm2 (1:500) (Calbiochem, San Diego, CA) and
mouse monoclonal anti-β-actin (1:25,000) (Sigma, St. Louis, MO) antibodies were used
to detect VDR, p21, Shh, p63, Hdm2 and β-actin expression respectively. Appropriate
IgG conjugated with horseradish peroxidase was used as secondary antibody (Promega,
Madison, WI). The membrane was washed thrice with 1X TTBS for 15 min each and
then exposed to Super-signal West Pico Chemiluminescent Substrate Kit (Pierce,
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Rockford, IL) for 1 min to detect the chemiluminescent signal. The protein was
visualized using FUJI FILM LAS3000 image reader. The antibodies were stripped from
the membrane by incubating the blot in Western Stripping Buffer (25 mM glycine, 1%
SDS, pH 2.0) for 30 min twice, at room temperature on a rocker. This was followed by
washing the blot for 5 min twice with 1X PBS. The membrane was then blocked with 5%
blocking milk followed by subsequent immunoblotting with another primary antibody
according to the method indicated.

4. RNA isolation and TaqMan based real time PCR: For RNA studies, cells were
transfected with desired expression plasmid. At 24 hr post-transfection, cells were
washed with 1X PBS and lysed directly on the culture plate using the RNAeasy method
as per manufacturer’s protocol (Qiagen, Valencia, CA). The RNA was quantified by
diluting 2μL of RNA sample with 98μL of TE buffer (10 mM Tris-Cl, 1 mM EDTA, pH
8.0). This sample mix was then transferred into a quartz cuvette; the absorbance was
measured using spectrophotometer at A260/A280 nm. The readings were taken relative to
the blank TE. The RNA concentration was determined by using the following relation:
RNAconc = (40 μg/ mL)*(A260)*(dilution factor)*(1 mL/1000 μL), assuming A260 of 1
corresponds to 40 μg of RNA per mL. The purity of RNA was estimated by the ratio of
A260/A280, with pure RNA having a ratio from 1.8-2.0. Each RNA sample was reverse
transcribed individually using random hexamers to create cDNA. Briefly, 1 μg of total
RNA was mixed with 2.5 μL of 10X TaqMan RT buffer, 5.5 μL of 25 mM MgCl2, 5.0 μL
of deoxyNTPs, 1.25 μL of random hexamers, 0.5 μL of RNase inhibitor, 0.625 μL of
Multiscribe reverse transcriptase, and RNase-free water for a total reaction volume of 25
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μL to synthesize cDNA by using TaqMan reverse transcription kit (Applied Biosystems,
Foster city, CA).The reverse transcription (RT) reaction was performed in a Perkin Elmer
Gene Amp PCR System 2400 programmed to sequentially cycle as follows: initial 10
min incubation at 25oC, 30 min RT step at 48oC, 5 min inactivation step at 95oC, and an
infinite hold at 4oC. After the RT reaction was complete, cDNA was diluted 1:2 by
adding 25 μL sterile DNAse/RNAse free water to each sample prior to storage at -20oC.
Quantitative real-time PCR analysis was performed in a 96 well micro titer plate format
on an ABI Prism 7900HT sequence detection system using TaqMan Universal master
mix and Assay on Demand reagents. Briefly, a 20 μL reaction was prepared by mixing 2
μL of cDNA sample, 10 μL of TaqMan Master Mix, 7 μL of DNAse/RNAse water and 1
μL of AOD (Applied Biosystems) containing forward and reverse primers and a
fluorescent TaqMan probe, designed and optimized for gene of interest for use in a 96
well plate format. The PCR conditions used were 2 min hold at 50oC, 10 min hold at
95oC and 40 cycles of 15 sec 95oC denaturation step and 1 min 60oC annealing and
elongation step. Each sample was analyzed using SDS 2.0 software (ABI) in triplicate for
target gene specific for VDR (Hs_ 0017213_m1), p21 (Hs_00355782_m1), Hdm2 (Hs_
00242813_m1) and Shh ((Hs_ 00179843_m1) (PE Applied Biosystems, Foster City,
CA). GAPDH was used as an internal normalization control. These primers were
designed by ABI, to span intron-exon junction, eliminating the possibility of detecting
genomic DNA. Each well was monitored for fluorescent dye and signals were considered
significant if the fluorescence intensity significantly exceeded the standard deviation of
the basic fluorescence, defined as the threshold cycle (CT). Relative mRNA quantitation
was performed using the comparative ∆∆Ct method (Caserta et al., 2006). Briefly, any
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sample that deviated by more than half a CT was excluded from the analysis. The RQ
value for each sample from the triplicate conditions was determined and compared to the
average GAPDH values. The average RQ values were graphed; the error bars represent
the standard deviation from the triplicate conditions.

5. Immunoprecipitation Assay: H1299 cells were seeded at a density of 4.5 x 105 cells/6 cm
plate. At 24 hr after plating the cells, expression plasmids encoding HA tagged wildtype
TAp63γ and GST tagged TAp63γ mutants were transiently transfected either alone or in
combination, as indicated. Cells were washed with 1X DPBS and then harvested for total
protein using RIPA (radioimmunoprecipitation assay) buffer (0.5% sodium deoxycholate,
1% NP40, 0.1% SDS, PBS, pH 7.4) mixed with 1% PIC (Sigma). Briefly, total protein
was pre cleared with 20 μL of recombinant-protein G-sepharose beads (Invitrogen,
Carlsbad, CA) for 1 hr at 4oC. After pre clearing beads were removed by centrifugation at
13,000 rpm for 1 min. The total protein was incubated with rotation for O/N at 4oC with
1 μg of monoclonal anti-HA 12CA5 antibody (Roche Diagnostics, Indianapolis, IN).
Next day immunoprecipitated samples were incubated with rec-protein G-sepharose
beads for 1 hr followed by four washes with RIPA buffer to remove the unbound
proteins.

Immunoprecipitated samples with beads were run on 10% SDS gel and

immunoblotted with rabbit polyclonal anti-GST Z5 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA).

6. Immunofluorescence studies: H1299 cells were plated on sterilized coverslips at a density
of 1.5 x 105cells/well of a 6 well plate. At 24 hr after seeding, expression plasmids
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encoding HA-tagged wildtype TAp63γ or GST tagged TAp63γ mutants were transiently
transfected either alone or in combination. For immunofluorescence staining, after
washing with 1X DPBS, colonies were fixed for 8 min with 3% paraformaldehyde and
permeabilized for 20 min with 1.0% Triton X-100. Cells were blocked with 0.5% normal
goat serum (NGS) and incubated with primary antibodies for 1 hr at room temperature.
Primary antibodies used to detect HA-TAp63γ wildtype and GST tagged mutants were
mouse monoclonal anti-HA 12CA5 (Roche Diagnostics, Indianapolis, IN) at a dilution of
1:100 and rabbit polyclonal anti-GST Z5 (Santa Cruz Biotechnology, Santa Cruz, CA) at
1:200. After three washes with 0.5% (NGS), cells were incubated with secondary goat
anti-rabbit, fluorescein isothiocyanate (FITC)-conjugated immunoglobulin G (IgG)
antibody (Jackson Immunoresearch, West Grove, PA, USA) at a dilution of 1:250, and
secondary donkey anti-mouse, texas red (TR) dye-conjugated IgG antibody (Jackson
Immunoresearch, West Grove, PA, USA) at a dilution of 1:275 for 1 hr at room
temperature. Hoechst dye 33342 (Sigma, St. Louis, MO) was used for nuclear staining.
Preparations were examined using fluorescence microscopy.

7. Flow cytometry: H1299 cells were plated at a density of 2.25 x 105 cells/6 well plate and
co-transfected with expression plasmids encoding membrane bound hybrid-US9GFP
(PAB35) with either TAp63γ or TAp63γ mutants or empty vector using Lipofectamine
2000. Membrane bound GFP plasmid (PAB35) was cotransfected along with either
TAp63γ or TAp63γ mutants, to distinguish the transfected cells from the non-transfected
cells. Healthy cells were used as a control for this experiment. At 48 hr post transfection,
cells were harvested for flow cytometry. Cells were collected by trypsinization using
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0.25% Trypsin-EDTA (Gibco), pelleted by centrifugation at 12,000 rpm for 5 min and
resuspended in phosphate-buffered saline (1X PBS). Two volumes of cold, 70% ethanol
were added dropwise, while vortexing and the samples were stored at 20°C until the day
of analysis. At that time, cells were pelleted as mentioned above and resuspended in
staining solution (50 μg/mL Propidium Iodide, 32 μg/mL RNase A (Sigma, St Louis,
MO) in PBS). Samples were moved to flow tubes and stored at 4°C for at least 1 hr in the
dark prior to analysis.

Flow cytometric analysis for GFP and Propidium Iodide

(PI) fluorescence was performed using CellQuest software (Becton Dickinson
Immunocytometry Systems (BDIS), San Jose, CA). For each analysis 10,000 gated
events were collected to permit cell cycle analysis of all cells and GFP cell
subpopulations. The GFP and PI fluorescence signals were separated with a 560
shortpass dichroic mirror and collected with a 530/30 bandpass (FL1, GFP) and 572/26
bandpass (FL2, PI). Data analysis was performed using CellQuest (BDIS). The GFP
fluorescence was collected on a logarithmic scale and the PI fluorescence was collected
on a linear scale.

8. Colony Formation Assay: H1299 cells were seeded at a density of 2.5x105 cells/well in a
6 well plate and transfected with expression plasmids encoding TAp63γ, TAp63γ mutants
or vector using Lipofectamine 2000 as indicated. At 24 hr post transfection, cells were
trypsinized in 500 μL of 0.25% Trypsin-EDTA (Gibco), pelleted and resuspended in
fresh complete media for counting. From each condition 1000 cells were counted on a
hemocytometer and then replated in each well of a 6 well plate, media was changed after
every 2 days. After 15 days of seeding and monitoring cell growth, the media was
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aspirated and cells were washed with 1X DPBS and 1 mL of crystal violet dye (0.1%
crystal violet in 10% ethanol) was added to each well for 5 min. The plates were
subsequently washed with water twice and left to dry at room temperature for 2 days. At
this point the pictures for each of the samples were taken. Subsequently, 1 mL of 10%
acetic acid was added to destain the cells for 30 min at RT. 100 µL of this destained
solution from each well was transferred to 96 well plate and read at 590 nm using
spectrophotometer.

9. RNA isolation/cRNA preparation: Cells were lysed directly in culture plate and total
RNA was isolated using the RNAeasy method as per manufacturer’s protocol (Qiagen,
Valencia, CA). The RNA was quantified by spectrophotometer reading at 260 nm and
integrity of the total RNA was determined by agarose gel electrophoresis and by
spectrophotometer reading ratio at 260/280. A ratio of 1.8-2.0 was considered optimum
for further analysis. First strand cDNA synthesis was performed with 5 µg of total RNA,
100 pmols of T7-oligo (dT) primer and 200 units of Superscript II enzyme (Invitrogen).
RNase H-dependent second strand synthesis was performed using 10 units of DNA ligase
and 40 units of DNA polymerase I. The double-stranded cDNA was purified using
GeneChip Sample Cleanup Module (Affymetrix, Inc., Santa Clara, CA). Biotin-labeled
cRNA was prepared employing GeneChip IVT Labeling Kit (Affymetrix) according to
manufacturer’s protocol, using T7 RNA polymerase and biotinylated nucleotides to
produce a labeled single stranded cRNA. The cRNA was purified using GeneChip
Sample Cleanup Module and quantified using Agilent (PE Applied Biosystems, Foster
City, CA) Bioanalyzer. 20 μg of cRNA was used for fragmentation utilizing GeneChip
Sample Cleanup Module as per manufacturer’s protocol. A small portion of the
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fragmented and non fragmented cRNA was subjected to agarose gel electrophoresis to
assess quality of cRNA and fragmentation reaction.

10. Array hybridization and scanning: 15 μg of fragmented cRNA along with non eukaryotic
spike controls were hybridized to Affymetrix HG-U133A GeneChips containing 39,000
transcript variants. Hybridization was performed for 16 hr in an Affymetrix GeneChip
Hybridization oven 640 at 45oC using constant rotation at 60 rpm. GeneChips were
subjected to washing and staining on Affymetrix GeneChip Fluidics Station 400
according to manufacturer’s protocol. Immediately after staining, the GeneChips were
scanned at 570 nm on an Affymetrix Scanner 3000 following protocols developed by
Affymetrix for the HG-U133A arrays. The digitized images from the scanned chips were
processed using Affymetrix Microarray Suite (MAS) version 5.0 and global scaling to a
target intensity of 150 was applied to all chips prior to analysis.

11. Data Mining: All analyses were performed using Affymetrix MAS5.0 and GeneSpring
version GX7.3.1. The Affymetrix CHP files were first imported into GeneSpring. In
GeneSpring, the chips were normalized to the fiftieth percentile and each gene
normalized to its median relative expression. To identify the genes which were
modulated by each of the TAp63γ mutants when compared to wildtype TAp63γ, the
following data mining approach was employed. First, only those genes that were
identified as being present or marginal in at least two of the three replicates in the
condition where expression is expected using Filter on Flags were included in the lists.
Next, gene lists containing genes that showed at least a 2 fold or greater increases or
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decreases relative to wildtype TAp63γ using Filter on Fold Change were created. Based
on these criteria the genes that passed through both these filters were identified using
Venn diagrams from GeneSpring. The subset of genes that made it to both these lists
were then passed through ANOVA statistical tool for a statistical significance of p ≤ 0.05.
This approach made our data analysis more stringent. We also utilized NCBI PubMed
and OMIM for getting more functional description on these genes.

12. Functional pathway analysis: The list of genes with significant changes in gene
expression (both increases and decreases) based on the microarray experiments were
exported from GeneSpring into Ingenuity Pathways Analysis (IPA) 5.0 (Ingenuity
Systems, Redwood City, CA) to create pathway maps of interacting genes. The core
analysis identified the pathways from the canonical pathways that were significant to our
data sets. Genes from the data sets that were associated with a canonical pathway in the
Ingenuity knowledge base were considered for analysis.
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III. Results:

Differential effect of TAp63γ mutants on p53/p63 targets: We examined the effect of wildtype
TAp63γ and naturally occurring TAp63γ mutants on PG13-Luc, Hdm2-Luc and Maspin-Luc
reporters in H1299 (p53 -/-) and HCT116 (p53-/-) cells, all 3 targets shown to be regulated by
both p63 and p53 (Figure 4). As expected the wildtype TAp63γ significantly upregulated the
reporter activity of all reporters tested in both these cell lines. In addition, TAp63γ (R227Q) and
TAp63γ (R298Q) exerted similar effects as wildtype TAp63γ and showed significant
upregulation of all the reporters. Interestingly, TAp63γ (K194E) observed only in SHFM
syndrome led to a significant increase in all the 3 reporters tested. On the other hand, TAp63γ
(R280C) observed both in SHFM and EEC also upregulated PG13-Luc and Hdm2-Luc but did
not affect the Maspin-Luc reporter activity. Finally, TAp63γ (R279H), TAp63γ (R204W) and
TAp63γ (C306R) all observed only in EEC syndrome had little or no effect on the reporter
activity of all reporters tested. A summary chart of the results obtained from transactivation of
these 3 reporters in both H1299 and HCT 116 (p53-/-) cell lines indicating the fold change
relative to vector control is included (Table 1).
Next, we examined the effect of these mutants on endogenous transcript levels of Hdm2 and p21
(Figure 5A). H1299 cells were transfected with TAp63γ and TAp63γ mutants or empty vector
backbone and the relative expression of these genes was assessed using TaqMan based real time
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Figure 4: Differential effect of TAp63γ mutants on transactivation of p53/p63 targets. H1299 and
HCT116 p53-/- cells were transfected with PG13-Luc, Maspin-Luc and Hdm2-Luc reporter
alone (100 ng) or along with wildtype TAp63γ or TAp63γ mutants (1 µg) and CMV-R-Luc (10
ng) plasmids using Lipofectamine 2000. At 24 hr post transfection cells were harvested and
subjected to dual luciferase assay as per manufacturer’s protocol. Y-axis represents RLU/R-Luc
relative luciferase units normalized for transfection efficiency. Error bars represent standard
deviations.
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PG13-Luc

Hdm2 Luc

Maspin Luc

Samples

H1299

HCT -/-

H1299

HCT -/-

H1299

HCT -/-

Vector

1.0 ± 0.0

1.0 ± 0.1

1.0 ± 0.0

1.0 ± 0.0

1.0 ± 0.0

1.0 ± 0.0

WTp63

4.7 ± 0.0

6.1 ± 0.1

23.4 ± 0.0

7.0 ± 0.0

9.0 ± 0.0

2.2 ± 0.0

R279H

1.5 ± 0.0

2.3 ± 0.1

0.7 ± 0.0

0.6 ± 0.0

0.8 ± 0.0

1.3 ± 0.0

K194E

6.8 ± 0.0

5.6 ± 0.1

58.6 ± 0.0

18.1 ± 0.0

3.3 ± 0.0

7.1 ± 0.0

R204W

1.0 ± 0.0

1.4 ± 0.0

0.7 ± 0.0

0.9 ± 0.0

1.3 ± 0.0

1.5 ± 0.0

R227Q

4.6 ± 0.0

1.3 ± 0.0

36.8 ± 0.0

9.9 ± 0.0

7.6 ± 0.0

3.5 ± 0.0

R280C

12.8 ± 0.1

5.5 ± 0.0

4.9 ± 0.0

17.5 ± 0.0

1.2 ± 0.0

2.3 ± 0.0

C306R

0.8 ± 0.0

1.0 ± 0.0

0.7 ± 0.0

0.9 ± 0.0

1.9 ± 0.0

2.4 ± 0.0

R298Q

4.3 ± 0.0

1.6 ± 0.0

27.2 ± 0.0

7.2 ± 0.0

13.6 ± 0.0

3.4 ± 0.0
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Table 1: Summary of the transactivation data indicating the differential effect of TAp63γ
mutants on p53/p63 target genes. The numbers in the column represent the fold change relative
to empty vector control. The numbers in red and blue represent SHFM mutants (K194E and
R280C) and mutants that mimic wildtype p63 (R227Q and R298Q) respectively.
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PCR. Consistent with our results from the transactivation data (Figure 4) cells transfected with
TAp63γ, TAp63γ(R227Q), TAp63γ(R298Q), TAp63γ(K194E) and TAp63γ(R280C) showed a
significant increase in the Hdm2 and p21 transcript levels. Once again, TAp63γ(R279H),
TAp63γ (R204W) and TAp63γ(C306R) had little or no effect on the transcript levels of both p21
and Hdm2. Similar results were observed in HCT (p53-/-) (Figure 5). To correlate the increase in
transcript level of Hdm2 and p21 to s e results demonstrate that while TAp63γ(R227Q) and
TAp63γ(R298Q) mutants behave like wildtype p63, the mutants observed in SHFM syndrome,
TAp63γ (K194E and R280C) also significantly induce targets specific for both p53/p63. teady
state protein levels, we examined the effects of mutant p63 on the endogenous Hdm2 and p21
protein levels using immunoblot analysis. We observed a significant increase in both Hdm2 and
p21 protein expression levels in cells transfected with wildtype TAp63γ, TAp63γ (K194E),
TAp63γ (R227Q) and TAp63γ (R298Q) and a modest increase with TAp63γ(R280C) mutant
(Fig 5B). As shown in Figure 5 wildtype TAp63γ is highly unstable and both TAp63γ (R227Q)
and TAp63γ (R298Q) mutants (Figure 4) mimic wildtype TAp63γ not only in its ability to
transactivate target genes but are as unstable as its wildtype counterpart (Figure 5B).

TAp63γ(R227Q) and TAp63γ(R298Q) mimic wildtype TAp63γ in regulation of a p63 specific
target: Having demonstrated the differential effect of these naturally occurring mutants on gene
targets regulated by both p53 and p63, we then tested the ability of TAp63γ and TAp63γ mutants
to regulate Shh, previously shown by our laboratory to be a p63 specific target gene (Caserta et
al., 2006). We examined the effects of wildtype and mutant TAp63γ on the transcripts and
protein levels of Shh. As shown in Figure 6A and 6B, TAp63γ (R227Q) and TAp63γ (R298Q)
34

35

Figure 5: Differential effects of TAp63γ mutants on p53/p63 target genes at transcript and
protein levels. A) To determine the effect of wildtype TAp63γ and TAp63γ mutants on
endogenous target gene expression using TaqMan based real time-PCR, H1299 and HCT p53-/cell lines were transfected with 3 µg of TAp63γ or TAp63γ mutants or empty vector alone. At
24 hr post transfection, total RNA was extracted and target gene expression was evaluated using
RT-PCR. Y-axis represents fold change in Hdm2 and p21 transcript levels relative to vector
transfected cells. B) Immunoblot analysis was performed to confirm overexpression of p63 and
endogenous expression of p53 and p63 specific targets, Hdm2 and p21. Immunoblotting for βactin served as the loading control.
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Figure 6: TAp63γ(R227Q) and TAp63γ(R298Q) mimic wildtype TAp63γ in their ability to induce
Shh. A) Shh transcript level in H1299 and HCT-/- cells transfected with TAp63γ or TAp63γ
mutant’s expression plasmids was detected using TaqMan real time-PCR. The plasmid were
used at a concentration of 3 µg. Y-axis represents fold change in Shh expression relative to
vector transfected cells. B) Immunoblot analysis was performed to confirm the overexpression of
p63 and endogenous expression of p63 specific target, Shh. Immunoblotting for β-actin served as
the loading control.
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along with wildtype TAp63γ led to a significant increase in the Shh transcript levels and a
corresponding increase in the protein levels of Shh. These results further demonstrate that
TAp63γ(R227Q) and TAp63γ(R298Q) retain the transactivation ability of wildtype TAp63γ.

TAp63γ mutants do not affect TAp63γ mediated regulation of Hdm2: In order to assess the effects
of TAp63γ mutants on wildtype TAp63γ mediated transactivation of p53 responsive genes,
H1299 cells were transfected with Hdm2-Luc reporter along with TAp63γ alone or with
increasing doses of TAp63γ mutants as indicated (Figure 7). As expected, TAp63γ led to a
significant

increase

in

Hdm2

reporter

activity.

Interestingly

the

TAp63γ(R279H),

TAp63γ(R204W) and TAp63γ(C306R) mutants which were unable to transactivate Hdm2 by
themselves, did not inhibit wildtype TAp63γ mediated transactivation of Hdm2-Luc (Figure 7A,
7C and 7F). Mutants TAp63γ(K194E), TAp63γ(R227Q) and TAp63γ(R298Q) which by
themselves can induce Hdm2-Luc reporter activity did not result in a significant synergistic
effect when co-transfected with wildtype TAp63γ (Figure 7B, 7D and 7G). Finally,
TAp63γ(R280C) which induces a modest increase in Hdm2-Luc reporter activity led to a dose
dependent synergistic increase in Hdm2-Luc reporter activity when co-transfected with wildtype
TAp63γ (Figure 7E).

Next we examined the effects of TAp63γ mutants on wildtype mediated induction of endogenous
transcript levels of Hdm2 and p21 (Figure 8A). Consistent with our results from the
transactivation data (Figure 7) none of the TAp63γ mutants had any affect on TAp63γ mediated
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Figure 7: TAp63γ mutants do not affect the TAp63γ mediated transactivation of Hdm2 and p21
(p53/p63 common target). H1299 cell lines were co-transfected with the 100 ng of Hdm2-Luc
reporter alone or with wildtype HA-TAp63γ and GST-TAp63γ mutants alone or in combination
(in 1:2 and 1:4 ratios, where 1 corresponds to 200 ng of plasmid) as indicated using
Lipofectamine 2000. At 24 hr post transfection, whole cell extracts were subjected to Dual
Luciferase Assay. Y axis represents relative luciferase units normalized to transfection
efficiency.
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regulation of Hdm2 and p21 transcript levels. To correlate the effects of TAp63γ mutants on
wildtype mediated induction of transcript levels to steady state protein levels, we examined the
effects of mutant p63 on wildtype TAp63γ mediated induction of Hdm2 and p21 protein
expression levels. As shown in Figure 8B, none of the mutants affected wildtype p63 mediated
induction of Hdm2 and p21. Immunoblotting confirmed the overexpression of GST-TAp63γ
mutants and wildtype HA-TAp63γ. Immunoblotting for actin was used as a loading control.
Altogether, our data shows that TAp63γ mutants do not inhibit the wildtype TAp63γ mediated
induction of p53/p63 gene.

TAp63γ mutants observed in some EEC syndrome inhibit TAp63γ mediated Shh induction: We
examined the effects of TAp63γ mutants on wildtype TAp63γ mediated Shh-Luc reporter
activity and Shh protein expression, a target gene regulated by p63 but not p53 (Caserta et al.,
2006). This was achieved by transfecting H1299 cells with Shh-Luc reporter, wildtype TAp63γ
and TAp63γ mutants as indicated in Figure 8. We observed that TAp63γ induced transactivation
of Shh reporter was significantly inhibited by TAp63γ(R279H), TAp63γ(R204W) and
TAp63γ(R280C) mutants in a dose dependent manner (Figure 9A, 9C and 9E). Interestingly,
once again the TAp63γ(R227Q) and TAp63γ(R298Q) mutants (Figure 9D and 9G) show only a
modest increase in the transactivation of Shh reporter when co-transfected with wildtype
TAp63γ. Finally, although the TAp63γ(C306R) and TAp63γ(K194E) by themselves do not
induce Shh reporter activity, they do not affect the ability of wildtype TAp63γ to induce Shh
reporter activity (Figure 9B and 9F).
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Figure 8: TAp63γ mutants do not affect the TAp63γ mediated effects on its target gene expression
at transcript and protein levels. H1299 cells were transfected with either GST-TAp63γ mutants
alone or in combination with wildtype HA-TAp63γ in equal amounts (1.5 µg) using
Lipofectamine 2000 as indicated. A) Hdm2 and p21 transcript levels were detected using
TaqMan based real time PCR. Y axis represents the fold change in transcript levels relative to
vector transfected cells. B) Immunoblot analysis of cell extracts harvested at 24 hr post
transfection was resolved on SDS-PAGE and probed using anti-GST, anti-HA, anti-Hdm2, antip21 and anti-actin.
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Next we examined the effects of these mutants on endogenous expression of Shh and VDR
(Figure 10A). For this H1299 cells were transfected with either GST-TAp63γ mutants alone or in
combination with wildtype HA-TAp63γ and the relative expression of these genes was assessed
using TaqMan based real time PCR. Consistent with our results from the transactivation data
(Figure 9) cells transfected with TAp63γ(R279H), TAp63γ(R204W) and TAp63γ(R280C)
significantly inhibited the wildtype TAp63γ mediated induction of Shh and VDR transcript
levels.

To correlate the decrease in the transcript level of Shh steady state protein level, we then
examined the effect of mutant p63 on endogenous Shh protein level using immunoblot analysis.
We observed a significant inhibition of the Shh protein expression levels in cells transfected with
TAp63γ(R279H), TAp63γ(R204W) and TAp63γ(R280C) and a modest increase with
TAp63γ(R227Q) and TAp63γ(R298Q) as shown in Figure 10B. Also, the mutants
TAp63γ(K194E) and TAp63γ(C306R) as expected did not affect Shh expression both at
transcript and protein levels. Immunoblot analysis confirmed the overexpression of HA tagged
TAp63γ and GST tagged TAp63γ mutants. p21 was used as a positive control in immunoblot
analysis. Taken together our data shows that TAp63γ mutants observed in EEC syndrome
significantly inhibited the wildtype TAp63γ mediated induction of specific p63 gene (Shh).
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Figure 9: EEC mutants inhibit the wildtype TAp63γ mediated induction of Shh. H1299 cells were
co-transfected with the 100 ng of Shh-Luc reporter plasmid alone or with wildtype HATAp63γ alone or with increasing concentration of GST-TAp63γ mutants (1:2 and 1:4 ratios,
where 1 corresponds to 200 ng of plasmid) as indicated, using Lipofectamine 2000. At 24 hr post
transfection, whole cell extracts were subjected to Dual Luciferase Assay. Y axis represents
relative luciferase units normalized to transfection efficiency relative to empty vector transfected
cells.
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Figure 10: EEC mutants inhibit the wildtype TAp63γ mediated induction of p63 specific target
genes. H1299 cells were transfected with either GST-TAp63γ mutants alone or in combination
with wildtype HA-TAp63γ in equal amounts (1.5 µg) using Lipofectamine 2000 as indicated. A)
Shh and VDR transcript levels were detected using TaqMan based real time PCR. Y axis
represents the fold change in transcript levels relative to vector transfected cells. B) Immunoblot
analysis of cell extracts harvested at 24 hr post transfection was resolved on SDS-PAGE and
probed using anti-GST, anti-HA, anti-Shh and anti-actin.
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TAp63γ mutants do not affect the localization of wildtype TAp63γ: Having observed the
differential effect of TAp63γ mutants on the p53/p63 and p63 specific genes and the ability of
EEC mutants to inhibit wildtype mediated effects on p63 specific targets we next assessed
whether the effects of p63 mutants on induction of these genes could be as a result of effects of
these mutants on the localization of wildtype TAp63γ. For this, we co-transfected H1299 cells
with HA tagged TAp63γ alone or along with different GST tagged TAp63γ mutants. At 24 hr
post-transfection, immunofluorescence assays were performed to study the localization of both
wildtype and mutant p63. TAp63γ by itself was localized in the nucleus. The EEC mutants
TAp63γ(R279H and R204W) that lead to a dose dependent decrease in TAp63γ mediated
induction of Shh, a p63 specific target (Caserta et al., 2006), and TAp63γ(C306R) do not affect
the localization of wildtype TAp63γ (Figure 11). Additionally, TAp63γ(R280C) mutant which is
observed in both SHFM and EEC syndrome and also leads to a dose dependent decrease of
wildtype p63 mediated Shh induction, did not have any effect on the localization of wildtype
TAp63γ. Interestingly, TAp63γ(K194E) observed specifically in the SHFM syndrome, is the
only mutant that showed partial cytoplasmic localization, however it also did not affect the
localization of wildtype TAp63γ (Figure 12). Furthermore, TAp63γ(R227Q and R298Q) mutants
that mimic wildtype, when co-transfected with wildtype TAp63γ also did not affect its
localization (Figure 13). Taken together, we show that all the TAp63γ mutants by itself localized
to the nucleus and when co-transfected with wildtype TAp63γ did not affect the nuclear
localization of wildtype TAp63γ.
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Figure 11: TAp63γ mutants observed in EEC syndrome do not affect the localization of wildtype
TAp63γ. H1299 cells were transfected with GST tagged TAp63γ mutants alone (1 µg) or along
with HA-tagged wildtype TAp63γ (0.5 µg). At 24 hr post transfection, cells were fixed with 3%
paraformaldehyde. HA-TAp63γ and GST-TAp63γ mutant expression was detected using mouse
anti-HA and rabbit anti-GST primary antibodies and corresponding anti-mouse Texas Red and
anti-rabbit FITC-conjugated secondary antibodies. The nucleus was stained with Hoechst 33342,
and the cells were examined under fluorescence microscope.
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Figure 12: TAp63γ mutants observed in SHFM syndrome do not affect the localization of
wildtype TAp63γ. H1299 cells were transfected with GST tagged TAp63γ mutants alone (1 µg)
or along with HA-tagged wildtype TAp63γ (0.5 µg). At 24 hr post transfection, cells were fixed
with 3% paraformaldehyde. HA-TAp63γ and GST-TAp63γ mutant expression was detected
using mouse anti-HA and rabbit anti-GST primary antibodies and corresponding anti-mouse
Texas Red and anti-rabbit FITC-conjugated secondary antibodies. The nucleus was stained with
Hoechst 33342, and the cells were examined under fluorescence microscope.
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Figure 13: TAp63γ(R227Q) and TAp63γ(R298Q) mutants that mimic wildtype TAp63γ do not
affect its localization. H1299 cells were transfected with GST tagged TAp63γ mutants alone (1
µg) or along with HA-tagged wildtype TAp63γ (0.5 µg). At 24 hr post transfection, cells were
fixed with 3% paraformaldehyde. HA-TAp63γ and GST-TAp63γ mutant expression was
detected using mouse anti-HA and rabbit anti-GST primary antibodies and corresponding antimouse Texas Red and anti-rabbit FITC-conjugated secondary antibodies. The nucleus was
stained with Hoechst 33342, and the cells were examined under fluorescence microscope.
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Wildtype TAp63γ interacts with TAp63γ mutants: In order to confirm that the lack of effect on
localization of wildtype p63 was not in part due to the inability of the mutant p63 to interact with
wildtype p63, we next examined whether the mutant p63 can associate with wildtype p63. This
will also enable us to determine whether the p63γ mutants included in our study form heterotetramer complexes with wildtype p63. For this, H1299 cells were transfected with expression
vectors encoding GST-TAp63γ mutants in the presence or absence of wildtype HA- TAp63γ as
shown in Figure 14. Whole cell extracts were subjected to immunoprecipitation experiments
using anti-HA antibody against wildtype HA tagged TAp63γ (panel A) and subsequently
immunoblotted with anti-GST to detect GST tagged TAp63γ mutants. Subsequently, these blots
were also immunoblotted with anti-HA to confirm immunoprecipitation of wildtype HA tagged
TAp63γ. Our results clearly demonstrate that all the p63 mutants associated with wildtype p63.
Panel B represents whole cell extracts immunoblotted with anti-HA and anti-GST antibodies to
confirm the overexpression of the wildtype and mutant p63. In addition, we observed that
TAp63γ(R279H), TAp63γ(R204W), TAp63γ(C306R) and TAp63γ(R298Q) stabilized wildtype
TAp63γ (Figure 14B). Taken together, these results demonstrate that all the TAp63γ mutants
tested in this study interact with wildtype TAp63γ.

Differential effects of TAp63γ mutants on cell growth: TAp63 isoforms have been reported to be
involved in promoting apoptosis during development and cancer progression. In particular, p63
has been shown to be required for p53 mediated apoptosis in mouse embryonic fibroblasts
(Flores et al., 2002; Gressner et al., 2005a). Hence, the phenotypic features like syndactyly and
cleft lip palate observed in p63 mutation associated developmental syndromes might be due to
the perturbations in the apoptotic signaling pathways. To address that, we assessed the effects of
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Figure 14: Association between TAp63γ and TAp63γ mutants. A) H1299 cell were transfected
with either wildtype HA-TAp63γ alone (2.5 µg), GST-TAp63γ mutants alone (2.5 µg) or along
with HA-TAp63γ. At 24 hr post transfection, whole cell lysates were made. Aliquots containing
300 μg of protein were subjected to Immunoprecipitation using anti-HA mouse antibody.
Immunoprecipitates were resolved by SDS-PAGE gel and immunoblotted with anti-GST rabbit
antibody. B) To confirm the overexpression, of wildtype and mutant proteins, equivalent
amounts of protein from each transfection was fractionated onto a SDS PAGE and
immunoblotted with anti-HA mouse and anti-GST rabbit antibody
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TAp63γ mutants on cell survival and apoptosis, using colony formation assay and flow
cytometry, respectively. As expected based on transactivation data, TAp63γ(R227Q) and
TAp63γ(K194E)

led

to

reduced

levels

of

cell

proliferation

similar

to

wildtype

TAp63γ (Figure 15Α and 15Β). In contrast, TAp63γ(R279H) mutant showed an increased cell
growth when compared to wildtype TAp63γ (Figure 13Α & 13Β). Consistent with colony
formation assay data, TAp63γ(R227Q) and wildtype showed a significant induction of apoptosis
relative to vector (Figure 15C). In contrast, compared to wildtype p63, mutant TAp63γ(R279H)
showed significantly reduced levels of apoptosis, supporting our colony formation assay results
which shows that TAp63γ(R279H) promotes cell proliferation (Figure 15). Together, our data
demonstrates that TAp63γ mutants exert differential effects on cell survival and growth
inhibition, which might explain the phenotypic variations observed within p63 associated
diseases.

GeneChip data analysis using GeneSpring: The precise role of p63 mutations has not been well
defined but the distinct phenotypes observed in human developmental syndromes associated with
p63 mutants might be due to the differences in target genes regulated by these mutants. We
performed gene expression studies, to study if p63 missense mutations result in gain or loss of
function. Specifically, we investigated the differential regulation of target genes by these mutants
in H1299 cell lines by studying the gene expression profile and determining if the phenotype
associated with a specific p63 mutant occurs as a result of its effect on gene expression.
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Figure 15: Differential effect on TAp63γ mutants on cell growth. H1299 cells were transfected
with either 3 µg of TAp63γ or representative TAp63γ mutants as indicated. A) Schematic
representation of the colonies observed in these conditions after staining with crystal violet B)
Quantitative representation of the destained crystal violet using 1% acetic acid and absorbance
read at 590nm from the duplicate samples. Y axis represents percentage of cell growth relative to
wildtype TAp63γ. C) H1299 cells were co-transfected with either TAp63γ mutants or wild
TAp63γ and membrane bound hybrid-US9GFP (PAB35). Cells were harvested at 48 hr post
transfection, fixed in 70% ethanol and DNA stained with propidium iodide solution, as described
in Materials and Methods. DNA distribution was analyzed using Flow cytometry using
CellQuest Program. Graph represents fold apoptosis of the sub G1 cells positive for PI and
PAB35 (membrane bound hybrid GFP). Y –axis represents % apoptosis relative to wildtype
TAp63γ.
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Treatment

Induced Suppressed
29
141
31
41
117
30
38

K194E_v_p63γ
R280C_v_p63γ
R204W_v_p63γ
C306R_v_p63γ
R279H_v_p63γ
R227Q_v_p63γ
R298Q_v_p63γ

72
112
110
202
72
75
90

Table 2: Summary of the number of genes that were either upregulated or downregulated by
TAp63γ mutants when compared to wildtype TAp63γ.
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Data Mining was performed as described in the Materials and Methods section. The total number
of genes that were modulated with each of TAp63γ mutants relative to wildtype p63 control is
summarized in Table 2. The genes that made it to the decreased list are indicative of loss of
function while the genes that made it to the increased list indicate gain of function. Interestingly,
the EEC mutant TAp63γ(C306R) was the had approximately 200 genes suppressed when
compared wildtype p63. In addition, more than 100 genes were induced by TAp63γ(R280C) and
TAp63γ(R279H) mutants respectively when compared to wildtype TAp63γ.

Common gene alterations associated with TAp63γ mutants relative to wildtype TAp63γ: Analysis
of the gene targets clearly demonstrated that TAp63γ mutants induced numerous genes that are
known to play an important role in cell cycle control, apoptosis, differentiation, development,
proliferation, transcription control and signaling. Our data clearly shows that TAp63γ mutants
are involved in multiple signaling pathways. We first identified target genes that were regulated
by at least 4-7/7 TAp63γ mutants included in our study. By comparing genes that were
suppressed by TAp63γ mutants, we identified approximately 40 overlapping genes that were
suppressed in at least 4/7 when compared to wildtype TAp63γ (Tables 3, 4, 6 and 7).
Approximately, 20% of the genes that made it to our list are identified p63 targets - Cyclin
dependent kinase inhibitor 1C (CDKN1C), Insulin growth factor binding protein 3 (IGFBP3),
Ferredoxin reductase (FDXR) and Aquaporin3 (AQP3) (Perez and Pietenpol, 2007; Trink et al.,
2007). Of the genes not identified as p63 targets: Chemokine (C-X-C motif) receptor 4 (CXCR4),
Distal-less homeo box 5 (DLX5) and Nuclear receptor subfamily 2, group F, member 1 (NR2F1)
were of particular interest, since they are involved in different development processes (Chin et
al., 2007; Zhou et al., 2000; Zou et al., 1998). Our analysis of the genes that were regulated by all
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Fold Change relative to wildtype TAp63γ
Gene
Name

Gene
Symbol

207768_at

EGR4

Description
early growth
response 4

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

0.0922

0.185

0.174

0.329

0.212

0.11

0.155

Identified
as p63
targets
-

+

213348_at

CDKN1C

219750_at

TMEM144

Cyclin-dependent
kinase inhibitor 1C
(p57, Kip2)
transmembrane
protein 144

0.249

0.32

0.241

0.417

0.134

0.386

0.45

0.476

0.312

0.343

0.16

0.409

0.401

0.382

-

+
39248_at

AQP3

aquaporin 3

0.22

0.207

0.173

0.198

0.184

Table 3: Genes that were downregulated in all 7 mutants compared to wildtype TAp63γ
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0.199

0.168

Functions
apoptosis, atrophy,
proliferation
apoptosis, G1
phase, growth,
proliferation, S
phase, cell cycle
progression,
transformation, cell
viability,
morphology,
senescence
integral to
membrane
osmotic water
permeability,
survival, glycerol
permeability, water
permeability,
permeability

Fold Change relative to wildtype TAp63γ

Gene Name

204249_s_at

204364_s_at

209569_x_at

216248_s_at

217028_at

Gene
Symbol

D4S234E

Description
LIM domain only
2 (rhombotin-like
1)
receptor
accessory protein
1
DNA segment on
chromosome 4
(unique) 234
expressed
sequence

NR4A2

nuclear receptor
subfamily 4,
group A, member
2

CXCR4

chemokine (C-XC motif) receptor
4

LMO2

REEP1

K194E

0.376

0.0676

0.44

R280C

0.184

0.202

0.437

R204W

0.265

0.0791

0.345

C306R

0.225

0.255

0.497

R279H

0.239

0.178

0.262

R227Q

NR

NR

NR

R298Q

Identified
as p63
targets
-

differentiation,
sprouting

-

protein insertion
into membrane

-

dopamine receptor
signaling pathway

0.491

0.467

0.342

0.416

0.358

0.245

0.38

0.332

NR

0.345

0.102

0.147

0.115

0.268

NR

0.218

Functions

0.44

apoptosis,
differentiation,
anoikis, growth,
maturation, cell
cycle progression
migration,
chemotaxis,
development,
homing, fusion,
proliferation,
apoptosis, retention

Table 4: Genes that were downregulated in at least 6/7 mutants compared to wildtype TAp63γ. Abbreviation NR stands for ‘not
regulated’.
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7 TAp63γ mutants relative to wildtype TAp63γ identified 4 genes (Early growth response 4
(EGR4), CDKN1C, Transmembrane protein 144 (TMEM144) and AQP3) of which 2 genes
(AQP3 and CDKN1C) are identified p63 targets while EGR4 and TMEM144 are not known to
be regulated by p63 (Table 3). Furthermore, we identified 5 genes (LIM domain only 3 (LMO2),
receptor accessory protein 1 (REEP1), DNA segment on chromosome 4 234 expressed sequence
(D4S234E), nuclear receptor subfamily 4, group A, member 2 (NR4A2) and CXCR4) to be
downregulated by at least 6/7 p63 mutants in comparison to wildtype, none of these genes have
been shown to be regulated by p63 (Table 4). Analysis of genes that were induced by at least 4 of
7 TAp63γ mutants led to the identification of only 7 overlapping genes (Protein tyrosine
phosphatase, non receptor type 11 (PTPN11), zinc finger protein 37B (ZNF37B), Chac cation
transport regulator homolog 1 (CHAC2), zinc finger protein 236 (ZNF236), BCL2 binding
component 3 (BBC3), erythropoietin receptor (EPOR) and coiled-coil domain containing 71
(CCDC71)) when compared to wildtype TAp63γ (Appendix Table 8). In particular, the only
gene identified to be induced by 6/7 mutants was PTPN11, a bonafide oncogene that is mutated
in several cancer types ; is hyperactivated in solid tumors and is also required for Ras-Erk
cascade (Chan and Feng, 2007; Mohi and Neel, 2007) (Table 5). Additionally, BBC3(PUMA), a
known p63 target gene that can modulate cellular apoptosis through intrinsic pathway via
binding to Bcl-2 on mitochondria was induced by 4/7 TAp63γ mutants (Rocco et al., 2006).
EPOR another gene induced by 4 TAp63γ mutants, is a regulator of RBC formation and is
present on tumor cells (Udupa, 2006). EPO signaling inhibits apoptosis and promote cell
proliferation, differentiation and cell survival (Sytkowski, 2007). Taken together our analysis
suggested that the TAp63γ mutants significantly suppress gene involved in cell cycle arrest and
induce the genes involved in proliferation. The greater number of overlapping genes in the
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Fold Change relative to wildtype TAp63γ

Gene
Name

205867_at

Gene
Symbol

Description

PTPN11

protein tyrosine
phosphatase,
non-receptor
type 11
(Noonan
syndrome 1)

K194E

3.997

R280C

2.035

R204W

3.834

C306R

NR

R279H

2.616

R227Q

2.324

Table 5: Genes that were upregulated by at least 6/7 mutants compared to wildtype TAp63γ
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R298Q

4.172

Identified
as p63
targets

Functions

-

apoptosis,
differentiation,
morphology, growth,
proliferation, adhesion,
G2 phase,
transformation,
chemotaxis

decreased list when compared to wildtype TAp63γ is indicative of a loss of function being more
predominant with the p63 mutations.

Mutant specific alteration of genes regulated by TAp63γ mutants: To understand the mechanisms
of p63 related disorders, we generated a list of genes that were regulated by each of these
mutants specifically compared to wildtype TAp63γ using GeneSpring. Focusing on these genes
will help us identify the different genes that might be specifically regulated by these mutants
which would give us insight into the differential effect of these mutants exerted towards p53
and/or p63 target genes. We manually assigned functional categories to each gene using
information available at NCBI, Affymetrix (Netaffx), Gene Ontology browser from GeneSpring
and Ingenuity Pathway Analysis. The manual classification allowed us to uncover some new
potential targets of p63 mutants.

SHFM syndrome mutants:

K194E mutant: Our analysis of specific genes regulated by TAp63γ(K194E) mutant, observed
only in SHFM syndrome, stressed the role of K194E in regulation of genes involved in
apoptosis, cell proliferation, differentiation and development. We identified a total of 21 genes,
of which 9 were induced while the remaining suppressed compared to wildtype p63. Some of the
striking genes identified to be downregulated by K194E were T-box 2 (TBX2) and fibroblast
growth factor receptor 1 (FGFR1) (Appendix Table 9). The T-box of transcription factor,
Fibroblast Growth factor (FGFs) and its receptor, FGFR play an important role in embryogenesis
and limb development (King et al., 2006; Li et al., 2005; Xu et al., 1999). Tbx2 is expressed in
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the forelimb and the hindlimb in the mouse and involved in cell-type specification and
morphogenesis of mammary gland (Gibson-Brown et al., 1998; King et al., 2006; Naiche et al.,
2005; Rowley et al., 2004). Fgfr1 is primarily expressed in the mesenchyme of developing limb
buds, craniofacial bone and mammary gland development (Dillon et al., 2004; Li et al., 2005;
Rice et al., 2003; Xu et al., 1999). Overall, our analysis provides an insight into some target
genes that might play a pivotal role in the developmental deformities associated with the SHFM
mutants.

R280C (SHFM/EEC) mutant: This p63 mutation is observed in two different developmental
syndromes EEC and SHFM. We identified approximately 135 genes specifically regulated by
this mutant; almost 100 of these genes were induced while the remaining genes were suppressed
when compared to wildtype TAp63γ (Appendix Table 10). The more number of increases
suggest that this mutant has a gain of function effect. Analysis of these gene targets demonstrated
the role of R280C in regulating genes implicated in metabolic processes, apoptosis,
development, immune response, differentiation, cell viability and signaling. Although pro
apoptotic genes: Interferon gamma-inducible protein 16 (IFI16), protein tyrosine phosphatase
receptor type, O (PTPRO), Calpain 5 (CAPN5), Septin 4 (SEPT4) (Lee et al., 2006), etc were
induced in the screening for genes regulated by TAp63γ(R280C), genes related to cell viability
like Thyroid hormone receptor alpha (THRA), matrix metallopeptidase 7 protein (MMP7), etc
also increased when compared to wildtype TAp63γ. However, it should be noted that the proapoptotic genes are more abundant in the list of TAp63γ(R280C) regulated genes (Appendix
Table 9). Interestingly, most of these genes are also involved in development. IFI16 is a gene
known to modulate apoptosis and inhibit cell cycle progression and loss of this gene results in
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deregulation of p53-mediated apoptosis, leading to tumor disposition (Alimirah et al., 2007;
Kwak et al., 2003; Zhang et al., 2007). CAPN5, SEPT5 and PTPRO are highly expressed during
embryogenesis and have tumor suppressor like ability (Beltran et al., 2003; Dear and Boehm,
1999; Larisch, 2004; Motiwala et al., 2004). MMP7 is expressed in epithelial cells and has been
implicated in mammary gland tumorigenesis (Lynch et al., 2007; Sorrell et al., 2005). Thyroid
hormone receptors play a role in brain development, inhibition of cell death and stimulation of
cell growth which imparts oncogenic potential to this gene (Bernal, 2007; Thormeyer and
Baniahmad, 1999; Yoshioka et al., 2006). In addition to these, we also observed other
developmental genes like Transcription factor 3 (TCF3) (Kim et al., 2007) and laminin, alpha 4
(LAMA4) (Salmivirta and Ekblom, 1998) also upregulated by TAp63γ(R280C). The genes that
stood out amongst those downregulated when compared to wildtype TAp63γ were anti apoptotic
genes (V-yes Yamaguchi sarcoma viral oncogene homolog 1 (YES1), Ras guanyl releasing
protein 1 (RASGRP1) and FYN oncogene related YES (FYN)) and pro-apoptotic genes (S100
calcium binding protein A2 (S100A2), Cbp/p300 interacting transactivator, with Glu/Asp rich
carboxy-terminal domain, 2 (CITED2) and TNF receptor superfamily, member 6 (FAS))
(Arnaud et al., 2003; Feng et al., 2001; Oki-Idouchi and Lorenzo, 2007; Wang et al., 2007).
S100A2 and CITED2 are both known targets of p63 and have been shown to play a role in
keratinocyte differentiation (Lapi et al., 2006; Vigano et al., 2006). Taken together our analysis
classified R280C as a gain of function mutant involved in regulation of genes involved in
different cellular processes.

EEC syndrome mutants:
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R204W mutant: TAp63γ(R204W) mutant which is observed in EEC syndrome regulates about
40 genes, 31 of which are downregulated while 9 are upregulated when compared to wildtype
TAp63γ (Appendix Table 11). Many genes involved in regulation of transcription factors (ELK4
ETS domain protein (ELK4), Regulatory factor X,3 (RFX3), TEA domain family member 1
(TEAD1), Amyotrophic lateral sclerosis 2 chromosome region, candidate 8 (ALS2CR8), etc)
and metabolic processes (Matrix metallopeptidase 1 (MMP1), Iduronate 2-sulphatase (IDS),
Glycine amidinotransferase (GATM), Dehydrogenase E1 and transketolase domain containing 1
(DHTKD1), ABO blood group transferase A alpha 1-3 galactosyltranferase (ABO),
Dehydrogenase/reductase SDR family, member 9 (DHRS9), etc) are downregulated specifically
by TAp63γ(R204W). Jagged 2 (JAG2) which is a ligand for NOTCH signaling, involved in
apoptosis, proliferation and differentiation in many different tissues and is a known target of p63
is also downregulated by R204W (Sasaki et al., 2001). JAG2, plays a primary role in cleft palate,
oral differentiation and craniofacial development observed in EEC patients (Casey et al., 2006).
MMP1 is a zinc dependent protease, involved in invasiveness, proliferation and malignancy by
degrading extracellular matrix (Seiki, 2003). Moreover, Tumor necrosis factor receptor
superfamily member 11B (TNFRSF11B), that plays a role in cell viability, anoikis and
differentiation is the gene positively regulated by TAp63γ(R204W) (Holen and Shipman, 2006).

C306R mutant: TAp63γ(C306R) observed in EEC syndrome is the most dominant negative
mutant with approximately 120 genes downregulated and only about 20 genes upregulated when
compared to wildtype TAp63γ, suggesting that it is a loss of function mutant (Appendix Table
12). Amongst the other developmentally related genes the most prominent genes downregulated
by this mutant are Folate receptor 1 (FOLR1), Transforming growth factor, beta 2 (TGFB2) and
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UDP-glucose ceramide glucosyltransferase (UGCG), which are involved in early embryonic
development with cleft palate and cleft lip with or without cleft palate and hypodontia (Bianchi
et al., 2000; Piedrahita et al., 1999; Slayton et al., 2003). The suppression of TGFB2 and FOLR1
is particularly intriguing, since p63 knock out mice also shows craniofacial and limb defects, as
well as corneal epithelial abnormalities similar to the knock out phenotype of these two genes.
Many receptors (FOLR1, Coagulation factor 2 (F2R), RPA interacting protein olfactory
receptor, family 5, subfamily T, member 2 (RPAIN) and Nuclear factor receptor subfamily 2,
group F, member 2 (NR2F2), etc) and kinases (G protein coupled receptor 6 (GRK6),
Adrenergic beta receptor kinase 2 (ADRBK2) , PI3 kinase regulatory subunit 3 (PIK3R3), etc)
are downregulated by TAp63γ(C306R) mutant. There were almost similar number of decreases
in genes involved in survival (FOLR1, Growth differentiation factor 15 (GDF15), Integrin alpha
V (ITGAV), etc) and apoptosis (Fibronectin 1 (FN1), Mixed lineage leukemia (MLL), Activating
transcription factor 2 (ATF2), Cullin2 (CUL2), Cyclin dependent kinase 6 (CDK6), etc). In
addition to these genes, other genes involved in metabolic processes, transport and immune
response were also downregulated by C306R mutant. Taken together our data suggests that
C306R mutant downregulates more genes than any other mutant making it a loss of function
mutation, involved in multiple signaling pathways.

R279H mutant: TAp63γ(R279H) which is observed exclusively in EEC related disorders and is
known for its dominant negative effects on wildtype mediated TAp63γ mediated induction of its
target genes, surprisingly had more number of genes induced than repressed, suggesting it is a
gain of function mutant. We identified approximately 80 genes that increased and only 6 genes
that decreased when compared to wildtype TAp63γ (Appendix Table 13). The most striking gene
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upregulated by this mutant was GLI- Kruppel family member 2 (GLI2), which is involved in
development of cleft palate, hair follicles, mammary gland and limbs (Slayton et al., 2003). The
knock out phenotype of GLI2 mice is similar to the phenotype observed with p63 knock out.
Another gene that was induced by R279H mutant specifically was Bcl2 related protein A1
(BCL2A1), an anti-apoptotic gene which has been shown to suppress apoptosis induced by p53
tumor suppressor gene (D'Sa-Eipper et al., 1996). The genes involved in cell cycle progression
and cell viability (Thioredoxin interacting protein (TXNIP), Calbindin 1 (CALB1), Androgen
receptor (AR), etc) were also induced in our analysis in comparison to wildtype TAp63γ
supporting or results from cell proliferation assays where TAp63γ(R279H) had enhanced cell
survival and decreased cell death when compared to wildtype TAp63γ. The genes that were
downregulated by R279H mutant when compared to wildtype TAp63γ included Matrix
metallopeptidase 12 (MMP12), Inhibin alpha (INHA), Bone morphogenetic protein 1 (BMP1),
etc which are involved in cellular processes like invasiveness, proliferation and differentiation.
Overall, our data indicates that the R279H mutant is not simply a dominant negative, but also
upregulates numerous genes when compared to wildtype p63, making it a gain of function
mutant.

R227Q mutant: TAp63γ(R227Q) is localized to the DNA binding domain and belongs to the
EEC syndrome category. However, it is different from the other EEC mutants observed within
this syndrome owing to its ability to exert similar effects are wildtype TAp63γ. Also, it lacks
some distinctive phenotypic characters like orofacial clefting, observed in other EEC mutation
phenotype. About 24 genes were downregulated and 19 genes were upregulated specifically by
TAp63γ(R227Q) when compared to wildtype TAp63γ (Appendix Table 14).
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The genes

suppressed by this mutant are involved in development, regulation of transcription, metabolite
transport and differentiation. The key functional categories among the genes that were
upregulated by TAp63γ(R227Q) compared to wildtype TAp63γ, involved those playing a role in
signal transduction, apoptosis and cell cycle arrest. It is interesting to note that the genes
involved in development (Retinoic acid receptor, alpha (RARA), Acrosomal vesicle protein 1
(ACRV1), Laminin alpha 5 (LAMA5), etc) were suppressed by this mutant, suggesting the
impact of this regulation in relation with the developmental defects associated with the p63
mutant phenotype. The most interesting gene identified is RARA due to its involvement in
craniofacial development which is a hallmark feature observed in EEC syndrome patients
(Houdayer and Bahuau, 1998). Furthermore, LAMA5 has been shown to play a crucial role in
kidney and dental embryonic development and hair morphogenesis (Fukumoto et al., 2006;
Kikkawa and Miner, 2006; Li et al., 2003). In agreement with our results from cell proliferation
and cell death assays wherein TAp63γ(R227Q) mutant behave like wildtype TAp63γ in its
ability to induce apoptosis, we identified genes with tumor suppressive abilities (Glucocorticoid
receptor DNA binding factor 1 (GRLF1) and Mitochondrial tumor suppressor 1 (MTUS1)) to be
induced by this mutant when compared to its wildtype counterpart (Yu et al., 2005). Both
GRLF1 and MTUS1 have been shown to restrict the growth of malignant glioma and pancreatic
tumors respectively (Seibold et al., 2003; Tikoo et al., 2000).

ADULT syndrome mutant R298Q: TAp63γ(R298Q) mutation is observed only in ADULT
syndrome. We identified approximately 25 genes which were downregulated and 10 genes
upregulated when compared to wildtype TAp63γ (Appendix Table 15). In addition to antiapoptotic genes (Deoxyribonuclease I-like 3 (DNASE1L3), Interleukin 1, alpha (IL1A) and
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protein phosphatase 2, regulatory subunit B, beta isoform (PPP2R2B), etc) and pro-apoptotic
genes (Sin3-associated polypeptide, 18kDa (SAP18) and Phospholipase A2, group VII
(PLA2G7), etc), we also identified genes involved in development (B cell CLL/lymphoma 11A
(BCL11A) and Lysyl oxidase-like 1 (LOXL1)) in the decreased lists. Interestingly, although both
pro apoptotic and anti apoptotic genes are repressed by R298Q mutant when compared to
wildtype TAp63γ, the former is more abundant than the later. BCL11A, a kruppel like zinc
finger transcription factor, is not only required for normal skeletal and lymphoid development
but is a proto-oncogene involved in different malignancies (Ganss and Jheon, 2004; Liu et al.,
2003; Satterwhite et al., 2001). LOXL1 acts as a tumor suppressor gene owing to its ability to
antagonize the ability of Ras-Erk to promote cell survival and is also involved in notochord
development (Gansner et al., 2007; Wu et al., 2007). Amongst the genes that was identified to be
induced, Plexin domain containing 1 (PLXDC1) plays a role in development and tumor
invasiveness and poor survival of osteogenic sarcoma patients (Fuchs et al., 2007).

Ingenuity pathway analysis: Furthermore, the combined list of genes that were regulated by at
least 4/7 TAp63γ mutants when compared to wildtype TAp63γ with GeneSpring was analyzed
using Ingenuity Pathway Analysis (IPA) software to identify unique networks involving these
genes. These networks represented relationships between the genes identified in our analysis and
other genes thereby giving us information on possible genes upstream or downstream of the
targets identified in this study. Several different pathway maps were created from this gene list
which helped us identify unique interactions between genes and proteins that they might encode.
The network represented in Figure 16 includes the genes which not only includes the greatest
number of the gene targets identified by our data mining strategy but also showed greatest fold
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changes of gene expression in either direction. We also ran the list of genes that were specifically
regulated by each mutant to get an idea of the signaling pathways important for the role of p63 in
development. Here, we represent a map from R279H, a gain of function mutation (Figure 17). It
is interesting to see the network is coded red for the most part suggesting the gain of function.
Also, the network contains numerous genes that are involved in different developmental
signaling pathways.
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Figure 16: IPA of the relationships between the genes that were both upregulated and
downregulated by TAp63γ mutants when compared to wildtype p63. The network shown here is a
graphical representation of the molecular relationships between genes/gene products. The color
scheme represents green (decreases) and red (increases). The higher intensity of color represents
a greater fold change. The lines connecting the nodes are curated from the literature. Solid lines
are direct relationships and the dashes lines are indirect relationships.
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Figure 17: IPA of the relationships between the genes that were both upregulated and
downregulated by R279H mutant when compared to wildtype p63. The network shown here is a
graphical representation of the molecular relationships between genes/gene products. The color
scheme represents green (decreases) and red (increases). The color intensity is proportional to the
fold change. The greater the fold changes the higher the color intensity. The more number of reds
indicate a gain of function. The lines connecting the nodes are curated from the literature. Solid
lines are direct relationships and the dashes lines are indirect relationships.
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IV. Discussion:

p63 plays an indispensable role in epithelial morphogenesis and cancer progression (Yang et al.,
1999). Pathogenic mutations of p63 are shown to be responsible for several human syndromes
exhibiting developmental defects. Although distinct p63 mutational patterns are observed with
each developmental syndrome suggesting a genotype-phenotype relationship, the impact of these
p63 mutations on gene expression and physiology of cell during development and cancer
progression are still not clear.

It has previously been reported that arginine codons 204, 227, 279 and 280 of p63 are important
for specific and nonspecific interactions with DNA target sequences, and mutations within those
residues are highly detrimental to DNA binding and transactivation activity (Celli et al., 1999).
Our studies also demonstrate that arginine mutants TAp63γ (R279H), TAp63γ (R204W) and
TAp63γ (C306R) lack the transactivation activity based on their inability to induce the
expression of Hdm2 and p21. Interestingly, p63 heterozygous mutant mice are more predisposed
to tumor formation (Flores, 2007; Flores et al., 2005). It is therefore possible that the inability of
TAp63γ (R279H), TAp63γ (R204W) and TAp63γ (C306R) mutant to induce cell cycle arrest
genes might predispose the patients harboring these mutations to a greater incidence of tumor
formation. Interestingly, many of these p63 mutations observed in EEC syndrome correspond
exactly to the hotspot mutations in p53 genes: p63 R204, R279, R280 are analogous to p53
R175, R248 and R249 respectively (Li and Prives, 2007) an exception being R227, which is
exclusive to p63. Alternatively, TAp63γ(R227Q) and TAp63γ(R298Q) mutants mimic its
wildtype counterpart in their ability to transactivate both p63/p53 and p63 specific targets, and
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therefore is less likely to increase the risk of these patients towards cancer development. The
apparent distinguishable transcriptional activity of TAp63γ(R227Q) is also supported by the fact
that, TAp63γ(R227Q) is a rare EEC mutation observed in only 1/227 EEC patients, lacks
orofacial clefting and has fewer limb defects than typically observed in EEC syndrome (Rinne et
al., 2006). Similarly, in spite of missense mutation in the DNA binding domain, the ability of
ADULT syndrome specific TAp63γ(R298Q) mutant to retain wildtype activity might be due to
presence of a second transactivation domain (Duijf et al., 2002; Propping et al., 2000; Reisler et
al., 2006). Additionally, a distinct phenotypic overlap between ADULT (R298Q) and EEC
(R227Q) syndromes has been reported (Reisler et al., 2006), which might reflect their ability to
retain the transcriptional potential of the wildtype TAp63γ.

Differential regulation of p53/p63 and p63 specific target genes by mutants associated with EEC
syndrome demonstrates that the molecular basis of phenotypic variation observed within the
EEC syndrome could be as a result of perturbation of different signaling pathways normally
regulated by p63. Our results showed that, while R279H mutant was unable to affect the TAp63γ
mediated induction of p53/p63 target genes; it significantly inhibited the wildtype p63 mediated
induction of p63 specific genes. This suggests that EEC mutant TAp63γ(R279H) may not always
act in a dominant negative fashion towards all target genes. Adding to this complexity, our
results showed that, while TAp63γ(R280C) and TAp63γ (K194E) mutants significantly induced
the p53/p63 responsive genes, these mutants did not induce the p63 specific target genes. Our
results are consistent with the observation that Arg 280 and Lys 194 amino acid residues
although involved in the maintenance of the overall structure of the DNA binding domain, when
mutated only has subtle effects on DNA-binding capacity of p63 (Ianakiev et al., 2000). It is
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therefore possible that subtle differences in the transactivation ability of these mutants might be
critical not only for the clinical variability observed in the same syndrome, but also other
pathogenic conditions observed with p53 and p63.

Furthermore, we demonstrated that TAp63γ(R279H), TAp63γ(R204W) and TAp63γ(R280C)
mutants act in dominant negative manner to inhibit the wildtype TAp63γ mediated
transactivation of p63 specific target genes. In contrast, TAp63γ(R227Q) and TAp63γ(R298Q)
significantly enhanced the wildtype p63 mediated transactivation. Wildtype p63 interacts with all
the mutants tested and localization of wildtype was not affected by any of the mutant which
suggests that the ability of mutants to inhibit wildtype activity might not be simply forming
heterotetramers, but could be due to the ability of dominant negative mutants to compete with
wildtype to bind to p63 specific responsive elements. Additionally, results from our interaction
studies (Figure 14) indicate that the mutants may be responsible in stabilizing the wildtype p63
which thereby leads to increased effects of wildtype p63 on its target genes when co-transfected
with p63 mutants.

Previous reports indicated that, exogenous TAp63 can activate genes involved in cell cycle arrest
and apoptosis (Fan et al., 2007b; Yang and McKeon, 2000). Consistent with transactivation
results, we demonstrated the differential ability of p63 mutants in promoting apoptosis. While
TAp63γ(R227Q)

and

TAp63γ(K194E)

mutants

significantly

promoted

cell

death,

TAp63γ(R279H) mutant significantly promoted the proliferation. The differential effect of
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mutants on cell survival may also dictate the complex phenotypic variation in p63 associated
diseases.

In order to understand the developmental program managed by p63 and the different p63
mutations observed in patients, the identification of transcriptional target genes is indispensable.
We performed GeneChip experiments in H1299 cells by overexpressing TAp63γ mutants to
identify genes that are commonly and specifically regulated by the mutants. H1299 cells were
used for these experiments because they lack endogenous p53 and any detectable levels of p63
isoforms. However, there is a limitation due to potentially non-physiologic amount of
overexpresssed protein that might positively influence genes that might not be activated by lower
levels of p63, or also repress genes by indirect mechanism. To date very little information is
available on the genes that are regulated by p63 in epithelial cells or ectodermal signaling, but
there is a good chance that there might be overlapping network of genes governing the various
phenotypic outcomes associated with p63 related syndrome. Our goal was to identify if the
distinct phenotype associated with the p63 mutations are due to regulation of some common and
different target genes by these mutants. In addition to the identification of some new potential
targets, our analysis confirmed some previously described targets as expected.

The mutation patterns observed in developmental syndrome associated with p63 have a
remarkable specificity. All these syndromes are associated with point mutations in the single p63
allele and are not a result of haploinsufficiency, as indicated from the knock out mouse model.
Our analysis of genes that were regulated by all mutants identified many genes suppressed by
p63 mutants when compared to wildtype p63 while only few genes were induced. Among the
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master regulators that were identified in the decreases compared to wildtype p63 were known
targets like CDKN1C (p57, Kip2), AQP3 and IGFBP3. Studies show that AQP3 is highly
expressed in the keratinocyte plasma membrane (Sougrat et al., 2002; Trink et al., 2007). The
downregulation of this gene by overexpression of the p63 mutants could lead to the gross
epithelial abnormalities observed in patients harboring p63 mutations. One particular observation
amongst the gene that were suppressed by at least 6/7 mutants (LMO2, REEP1, D4S234E,
NR4A2 and CXCR4) was that R227Q did not have any effect on these gene compared to
wildtype, once again supporting the previous reports, categorizing it as a rare mutation with
slightly different phenotype than the other EEC syndrome mutants. Additionally, FOXF1 and
CITED1 genes involved in proliferation were downregulated by SHFM and all EEC mutants
except R227Q and ADULT mutation R298Q. Interestingly, IGFBP3, another known target of
both p53 and p63 was downregulated by all mutants except R227Q and R298Q once again
suggesting that these two mutants retain the wildtype’s ability to induce its target gene and
supporting the observation that R227Q could be a ADULT syndrome mutant due to its
phenotypic overlap with R298Q (Reisler et al., 2006).

The rare patients with heterozygous deletion of single allele of p63, display no characteristic
signs of EEC syndrome (van Bokhoven et al., 2001), thereby suggesting that EEC syndrome
mutations could have a gain of function or loss of function effect. Our analysis identified EEC
syndrome mutations R279H and R280C as gain of function with greater number of genes
increased. IPA analysis of R279H mutant identified a network of genes that were all increased by
this mutant, thereby providing us with target genes that are already known to play a role in
development and provides information on the network of genes regulated by this p63 mutant.
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The other mutation identified to have a gain of function effect is R280C which is observed in
both EEC and SHFM having more genes induced than suppressed when compared to wildtype
p63. We identified genes involved in various metabolic processes, transport, development and
apoptosis to be regulated by this mutant. The unexpected functional category identified here was
immunity. It will be interesting to further investigate the role of p63 in this field, since p63 has
been shown to be expressed in the immune system (Yang et al., 1998). In agreement with our
earlier observation of R280C being able to induce p21, a cell death kinase inhibitor, we
identified various genes involved in cell cycle control to be specifically upregulated by R280C.

The most striking contribution of p63 relates to its importance in squamous cell differentiation,
skin renewal and development. Studies with p63 null mice clearly suggested the role of p63 is
epithelial morphogenesis. Our analysis showed C306R belonging to EEC syndrome as a loss of
function of mutant downregulating genes involved in different cellular processes like
development, cell death, differentiation and metabolic processes. Although the suppression of
these genes doesn’t necessarily indicate a complete blockade in the downstream signaling
cascade, it does result in some defective outcomes as observed in the EEC syndrome patients.
The NOTCH signaling is a critical regulator of differentiation and proliferation. Given the role of
JAG2 in cleft palate, oral differentiation and craniofacial development, an interesting observation
was that R204W mutation classified as a specific EEC syndrome downregulated this gene. One
of the reasons for the gross abnormalities observed in this particular mutant phenotype could be
the suppression of this signaling pathway. R204W suppresses multiple transcription factors; the
repression of these genes could be a basic event in the deregulation of developmental program
regulated by wildtype p63.
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NSCLP is one of the most congenital anomalies associated with p63 mutations. Retinoic acid
which is a derivative of Vitamin A is known to play an important role in development during
embryogenesis (Fan et al., 2007a). The dominant negative mutations of RA result in
developmental abnormalities including craniofacial defects (Houdayer and Bahuau, 1998). RA
interacts with RARA (Retinoic acid receptor, alpha) or RXR, therefore the regulation of this
gene by R227Q mutant observed in EEC syndrome suggests that it might be one of the critical
regulators of p63 signaling and the repression of this signaling pathway leads to the defective
phenotype observed in EEC syndrome. Furthermore, LAMA5 which was also downregulated by
R227Q has also been shown to play a crucial role in development of dental placodes and in hair
morphogenesis (Fukumoto et al., 2006; Kikkawa and Miner, 2006; Li et al., 2003). R298Q
observed in ADULT syndrome also regulated genes involved in various processes involved in
development, immune response, transport, apoptosis and cell viability. We identified Tbx2 as
one the genes downregulated by K194E, a SHFM syndrome mutant. Tbx2 has been shown to
play a role in limb morphogenesis (Manning et al., 2006); (Nissim et al., 2007). The suppression
of Tbx2 by K194E might lead to defects in limb development, a characteristic of SHFM
syndrome. Understanding the molecular biology of K194E mutant in regulating genes which are
important for normal limb and mammary gland development will aid in our understanding of the
phenotype observed in SHFM related developmental anomaly.

In conclusion, our data demonstrates that the different TAp63γ mutants vary in their ability to
transactivate p53/p63 and p63 target genes. Our analysis confirms that p63 plays a central role in
development by impinging on multiple pathways at the cross roads of development and
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apoptosis. Taken together our analysis provides information on the network of genes that are
regulated by the p63 mutants. Future direction will aim at validation of the target genes identified
by GeneChip analysis using real-time PCR and immunoblotting. The phenotypic variations
observed within p63 related syndromes could in part be due to the differential effects of these
mutants on canonical and non-canonical downstream signaling pathways of p63. Molecular
description of these developmental syndromes involving p63 will aid in finding strategies for
their recognition and alleviation. The identification of genes regulated by specific p63 mutants
will help in the linking of p63 into signaling pathways involved in limb morphogenesis,
differentiation and apoptosis. Undoubtedly, a better understanding of the effects exerted by these
mutants may improve our comprehension of developmental and cancer biology and aid in better
therapeutic strategies at least in cancers wherein over expression of ΔNp63α has been reported.
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V. Appendix
Fold Change relative to wildtype TAp63γ

Gene Name

Gene
Symbol

200974_at

ACTA2

203304_at

BAMBI

204529_s_at

TOX

205935_at

FOXF1

206752_s_at

DFFB

207144_s_at

CITED1

207813_s_at

FDXR

208054_at

HERC4

Description

actin, alpha 2,
smooth muscle,
aorta
BMP and activin
membranebound inhibitor
homolog
(Xenopus laevis)
thymus high
mobility group
box protein TOX
forkhead box F1
DNA
fragmentation
factor, 40kDa,
beta polypeptide
(caspaseactivated DNase)
Cbp/p300interacting
transactivator,
with Glu/Asp-rich
carboxy-terminal
domain, 1
ferredoxin
reductase
hect domain and
RLD 4

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

Identified
as p63
targets

NR

0.437

0.359

0.45

0.382

NR

0.483

+

Functions
morphology, adhesion,
polarization,
disassembly, cell
spreading, expansion,
morphogenesis,
maturation

0.434

NR

0.44

NR

0.435

0.377

0.157

-

colony formation

0.102

0.341

NR

0.327

0.474

NR

0.137

-

expansion, commitment

0.125

0.427

0.233

0.491

0.0996

NR

NR

+

Proliferation

condensation,
degradation, instability,
cell death, transformation

NR

0.411

0.404

0.121

NR

0.471

0.46

+

0.185

0.35

0.398

0.428

0.362

NR

NR

-

NR

0.296

0.268

0.234

0.312

NR

0.478

+

0.464

0.486

0.14

NR

0.266

0.427

NR

-
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aggregation, growth,
differentiation, cell death
apoptosis, survival,
growth, permeabilization
ubiquitin protein ligase
activity

Fold Change relative to wildtype TAp63γ

Gene Name

Gene
Symbol

213707_s_at

DLX5

214984_at

SMG1

Description

distal-less
homeo box 5
PI-3-kinaserelated kinase
SMG-1
ubiquitinconjugating
enzyme E2D 1
(UBC4/5
homolog, yeast)

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

Identified
as p63
targets

0.238

NR

0.409

0.353

0.38

NR

0.126

+

Functions
production,
morphogenesis,
development,
differentiation

NR

0.215

0.464

0.191

0.333

0.203

NR

-

DNA repair, amino
acid transport

0.37

0.376

NR

0.478

NR

0.474

0.276

-

BACE1

ataxin 3
beta-site APPcleaving
enzyme 1

0.392

NR

0.369

0.339

NR

0.459

0.464

-

protein modification
process; ubiquitindependent protein
catabolic process
cell death,
endoplasmic
reticulum stress
response
regulation, cell
death, degeneration,
deposition

RNASET2

ribonuclease T2

NR

0.371

0.477

0.379

0.484

NR

0.461

-

unknown

215957_at

UBE2D1

216657_at

ATXN3

217904_s_at
217983_s_at

NR

0.154

0.449

NR

0.275

0.254

0.0897

-

Table 6: Genes that were downregulated in at least 5/7 mutants compared to wildtype TAp63γ
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Fold Change relative to wildtype TAp63γ
Gene Name

Gene
Symbol

Description

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

Identified
as p63
targets

Functions
ciliogenesis, colony
formation,
morphology,
accumulation,
adhesion,
differentiation
differentiation,
proliferation,
adipogenesis, cell
cycle progression,
maturation,
apoptosis,
expansion,
morphology

200878_at

EPAS1

endothelial PAS
domain protein 1

0.196

0.423

0.393

NR

NR

0.244

NR

-

204039_at

CEBPA

CCAAT/enhancer
binding protein
(C/EBP), alpha

NR

NR

0.378

0.333

0.379

NR

0.434

-

0.139

0.212

0.444

NR

0.396

NR

NR

-

damage response

NR

0.288

0.474

NR

NR

0.459

0.414

-

interaction

0.458

NR

0.395

0.474

NR

NR

0.424

-

monocarboxylic
acid transport

205156_s_at

ACCN2

205535_s_at

PCDH7

207038_at

SLC16A6

amiloridesensitive cation
channel 2,
neuronal
BH-protocadherin
(brain-heart)
solute carrier
family 16
(monocarboxylic
acid
transporters),
member 6

92

Fold Change relative to wildtype TAp63γ
Gene Name

207141_s_at

Gene
Symbol

Description

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

Identified
as p63
targets

Functions

KCNJ3

potassium
inwardlyrectifying
channel,
subfamily J,
member 3

NR

0.433

NR

0.449

0.35

0.468

NR

-

potassium ion
transport

NR2F1

Nuclear receptor
subfamily 2,
group F, member
1

NR

0.442

0.443

0.342

NR

NR

0.484

-

209771_x_at

CD24

CD24 antigen
(small cell lung
carcinoma
cluster 4 antigen)

0.309

NR

0.465

NR

0.223

0.373

NR

+

210239_at

IRX5

iroquois
homeobox
protein 5

NR

0.444

0.449

0.447

0.471

NR

NR

-

209505_at

210387_at

HIST1H2BG

histone 1, H2bg

0.418

0.466

NR

0.49

NR

0.467

NR

-

210609_s_at

TP53I3

tumor protein
p53 inducible
protein 3

NR

0.419

0.417

0.411

0.349

NR

NR

+
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apoptosis,
development,
migration,
projection,
innervation,
cytostasis,
extension,
differentiation
binding, apoptosis,
adhesion,
proliferation,
motility,
invasiveness,
rolling, expansion
development and
cell death
nucleosome
assembly,
chromosome
organization and
biogenesis
induction of
apoptosis by
oxidative stress

Fold Change relative to wildtype TAp63γ
Gene
Symbol

Description

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

Identified
as p63
targets

Functions

CIITA

class II, major
histocompatibility
complex,
transactivator

0.495

0.47

0.417

NR

0.5

NR

NR

-

activation-induced
cell death

214586_at

GPR37

G proteincoupled receptor
37 (endothelin
receptor type Blike)

214850_at

GUSBP1

215342_s_at

RABGAP1L

Gene Name

210925_at

216379_x_at

217551_at

glucourinidase,
beta
pseudogene 1
RAB GTPase
activating protein
1-like

CD24

CD24 antigen
(small cell lung
carcinoma
cluster 4
antigen)

LOC441453

similar to
olfactory
receptor, family
7, subfamily A,
member 17

0.492

0.313

NR

NR

0.453

0.386

NR

-

cell death,
endoplasmic
reticulum stress
response,
hyperpolarization

NR

NR

0.44

0.37

NR

0.484

0.261

-

carbohydrate
metabolic process

NR

0.255

NR

0.47

0.115

NR

0.284

-

regulation of Rab
GTPase activity

+

binding, apoptosis
adhesion,
proliferation,
motility, cell
spreading,
invasiveness,
rolling, expansion

-

signal
transduction,
GPCR protein
signaling

0.479

0.439

0.437

NR

0.463

0.219

94

NR

0.388

0.369

0.212

NR

NR

NR

NR

Fold Change relative to wildtype TAp63γ
Gene Name

Gene
Symbol

218706_s_at

NS3TP2

219179_at

DACT1

219358_s_at

CENTA2

220860_at

PURG

221805_at

NEFL

Description
HCV NS3transactivated
protein 2
dapper,
antagonist of
beta-catenin,
homolog 1
(Xenopus
laevis)
centaurin,
alpha 2
purine-rich
element
binding protein
G
neurofilament,
light
polypeptide
68kDa

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

Identified
as p63
targets

Functions

NR

0.398

0.253

0.483

NR

NR

0.388

-

Unknown

0.445

NR

0.141

0.473

NR

0.403

NR

-

Wnt signaling
pathway, multicellular
organism
development

NR

0.439

0.37

0.445

0.468

NR

NR

-

GTPase activator
activity

0.366

0.323

0.357

0.292

NR

NR

NR

-

DNA binding

-

organization,
biogenesis, assembly,
dissociation,
clustering, apoptosis,
size

0.286

0.371

0.334

NR

NR

0.174

Table 7: Genes that were downregulated in at least 4/7 mutants compared to wildtype TAp63γ
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NR

Fold Change relative to wildtype TAp63γ

Gene Name

Gene
Symbol

Description

K194E

R280C

R204W

C306R

R279H

R227Q

R298Q

No. of
mutants in
which the
gene
expression
increased

215358_x_at

ZNF37B

zinc finger
protein 37b
(KOX 21)

2.946

2.959

NR

NR

2.436

3.146

3.7

5

-

unknown

219270_at

CHAC2

Chac, cation
tranport
regulator
homolog 1
(E.coli)

2.32

NR

2.571

2.713

3.383

NR

2.543

5

-

protein binding

222227_at

ZNF236

zinc finger
protein 236

2.049

2.474

2.576

3.38

2.513

NR

NR

5

-

211692_s_at

BBC3

BCL2 binding
component 3 ;
BCL2 binding
component 3

2.697

NR

2.963

NR

2.065

NR

2.393

4

+

215054_at

EPOR

erythropoietin
receptor

2.51

NR

2.489

NR

NR

2.026

2.242

4

-

219893_at

CCDC71

coiled-coil
domain
containing 71

2.04

NR

2.574

NR

2.064

2.068

NR

4

-

Table 8: Genes that were upregulated by at least 4/7 mutants when compared to wildtype TAp63γ
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Identified
as p63
targets

Functions

DNA dependent
regulation of
transcription
apoptosis, DNA
damage response,
permeabilization,
survival, cell death
proliferation,
differentiation,
mitogenesis, growth,
development, G1
phase, morphology,
apoptosis, G2/M phase
transition,

unknown

Gene Name

Gene
Symbol

K194E
Fold
Change

Description

Functions

interleukin 12B (natural killer
cell stimulatory factor 2,
cytotoxic lymphocyte
maturation factor 2, p40)

proliferation, activation,
differentiation, cytotoxicity,
stimulation, development,
polarization, apoptosis

Mdm4, transformed 3T3 cell
double minute 4, p53 binding
protein (mouse)
transmembrane protein 40

proliferation, apoptosis, growth, cell
death, cell cycle progression,
transformation, colony formation
integral to membrane
biogenesis, stability, fragmentation,
deformability, length, activation,
loss, contraction, anchoring

207901_at

IL12B

2.901

205655_at

MDM4

2.446

219503_s_at

TMEM40

3.123

206385_s_at

ANK3

2.314

209689_at

CCDC93

2.442

213496_at

LPPR4

2.296

216519_s_at

PROSC

2.408

219080_s_at

CTPS2

2.017

CTP synthase II

221915_s_at

RANBP1

2.101

RAN binding protein 1

40560_at

TBX2

0.472

T-box 2

204036_at

EDG2

0.411

endothelial differentiation,
lysophosphatidic acid Gprotein-coupled receptor, 2

201069_at

MMP2

0.454

matrix metallopeptidase 2

204483_at

ENO3

0.474

enolase 3 (beta, muscle)

205841_at

JAK2

0.222

206508_at

CD70

0.445

206615_s_at

ADAM22

0.477

210803_at

TXNRD2

0.328

ankyrin 3, node of Ranvier
(ankyrin G)
coiled-coil domain containing
93
plasticity related gene 1
Proline synthetase cotranscribed homolog

Unknown
Development
Enzyme
pyrimidine nucleotide biosynthetic
process
biogenesis, association, growth
immortalization, proliferation,
aging, growth, senescence, fate
determination
apoptosis, morphology, proliferation,
formation, migration, motility, cell
spreading, chemotaxis
invasion, migration, growth,
proliferation, apoptosis,
invasiveness, differentiation,
chemotaxis, tubulogenesis,
malignancy
Glycolysis

Janus Kinase 2

proliferation, apoptosis, growth,
transformation, differentiation,
mitogenesis, cell viability, binding,
G1 phase, survival

CD70 molecule

differentiation, apoptosis,
proliferation, depletion, necrosis,
signaling, interaction, cell cycle
progression

ADAM metalopeptidase
domain 22
Thioredoxin reductase 2
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proliferation, migration
cell death, hematopoiesis

Gene Name

Gene
Symbol

K194E
Fold
Change

Deascription

Functions

214337_at

COPA

0.455

coatomer protein complex,
subunit alpha

Phagocytosis

fibroblast growth factor
receptor 1

proliferation, outgrowth,
mitogenesis, growth, survival,
apoptosis, maturation, migration,
cell death, cell movement

215404_x_at

FGFR1

0.445

215783_s_at

ALPL

0.309

217632_at

GNL3L

0.496

Alkaline phosphatase,
liver/bone/kidney
guanine nucleotide binding
protein-like 3 (nucleolar)-like

Mineralization
nucleotide binding

Table 9: Genes that were specifically regulated by TAp63γ(K194E) mutant alone when
compared to wildtype TAp63γ. The fold change values above 2.0 indicate increases; while the
values less than 0.5 indicate decreases with K194E mutant when compared to wildtype p63. The
highlighted genes are the genes discussed in the result section.
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Gene Name

Gene Symbol

R280C
Fold
Change

208596_s_at

UGT1A10

5.069

202342_s_at

TRIM2

5.485

203399_x_at

PSG3

4.065

Description
UDP glucuronosyltransferase
1 family, polypeptide A10
tripartite motif-containing 2
Pregnancy specific beta-1glycoprotein 3

Function
metabolic process
protein binding
defense response

208966_x_at

IFI16

3.98

interferon, gamma-inducible
protein 16

differentiation, proliferation,
cell cycle progression,
apoptosis, contact growth
inhibition, morphology,
accumulation, DNA damage
response, G1/S phase
transition, osteogenesis

217578_at

XPO1

4.738

Exportin 1 (CRM1 homolog,
yeast)

intracellular protein transport

221778_at

JHDM1D

2.336

jumonji C domain-containing
histone demethylase 1
homolog D (S. cerevisiae)

Unknown

207142_at

KCNJ3

3.223

potassium inwardly-rectifying
channel, subfamily J, member
3

potassium ion transport

222005_s_at

GNG3

3.664

207051_at

SLC17A4

2.063

219761_at

CLEC1A

2.746

207602_at

TMPRSS11D

2.946

216415_at

DNAH3

2.191

219172_at

UBTD1

2.014

216818_s_at

OR2J2

6.463

215671_at

PDE4B

2.928

220735_s_at

SENP7

2.208

217319_x_at

CYP4A11 ;
CYP4A22

4.097

Guanine nucleotide binding
protein (G protein), gamma 3
solute carrier family 17
(sodium phosphate), member
4
C-type lectin domain family 1,
member A
transmembrane protease,
serine 11D
Dynein, axonemal, heavy
polypeptide 3
ubiquitin domain containing 1
olfactory receptor, family 2,
subfamily J, member 2
Phosphodiesterase 4B, cAMPspecific (phosphodiesterase
E4 dunce homolog,
Drosophila)
SUMO1/sentrin specific
peptidase 7
cytochrome P450, family 4,
subfamily A, polypeptide 11 ;
cytochrome P450, family 4,
subfamily A, polypeptide 22
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aggregation, growth, adhesion
Transport
cell surface receptor linked
signal transduction
proteolysis; respiratory
gaseous exchange
ciliary or flagellar motility;
microtubule-based movement
protein modification
signal transduction

catalytic activity

proteolysis, ubiquitin cycle
electron transport; fatty acid
metabolic process

Gene Name

Gene
Symbol

R280C
Fold
Change

Description

Function

220047_at

SIRT4

2.396

sirtuin (silent mating type
information regulation 2
homolog) 4 (S. cerevisiae)

chromatin silencing
differentiation, proliferation,
fusion, morphology,
transformation, production,
activity, size, apoptosis

1316_at

THRA

2.339

thyroid hormone receptor,
alpha (erythroblastic
leukemia viral (v-erb-a)
oncogene homolog, avian)

205552_s_at

OAS1

6.225

2',5'-oligoadenylate synthetase
1, 40/46kDa

Apoptosis

219938_s_at

PSTPIP2

4.91

proline-serine-threonine
phosphatase interacting
protein 2

Unknown

2.282

Transcription factor 3 (E2A
immunoglobulin enhancer
binding factors E12/E47)

apoptosis, development,
proliferation, differentiation,
growth, cell cycle
progression, lymphopoiesis,
morphology, G1 phase
proliferation, differentiation,
hyperproliferation, antiviral
response, activation, survival,
degeneration, apoptosis,
damage
chemotaxis, migration,
adhesion, infiltration, cell
movement, proliferation

216647_at

TCF3

210198_s_at

PLP1

13.8

proteolipid protein 1
(Pelizaeus-Merzbacher
disease, spastic paraplegia 2,
uncomplicated)

210772_at

FPRL1

3.528

formyl peptide receptor-like 1 ;
formyl peptide receptor-like 1

215231_at

PRKAG2

3.821

216402_at

SEC14L4

2.693

Protein kinase, AMP-activated,
gamma 2 non-catalytic subunit
SEC14-like 4 (S. cerevisiae)

202202_s_at

LAMA4

3.506

laminin, alpha 4

203961_at

NEBL

2.194

nebulette

204259_at

205092_x_at

MMP7

ZBTB1

fatty acid metabolism
Transport
migration, branching,
adhesion, binding,
alignment, development,
elongation, degeneration,
proliferation
ion transport; regulation of
actin filament length

2.161

matrix metallopeptidase 7
(matrilysin, uterine)

apoptosis, invasion,
proliferation, aggregation,
migration, malignancy, cell
movement, invasiveness,
differentiation, survival

2.828

zinc finger and BTB domain
containing 1

differentiation, proliferation,
fusion, morphology,
transformation, production,
activity, size, apoptosis
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Gene Name

Gene
Symbol

R280C
Fold
Change

Description

Function

calpain 5

apoptosis, invasion, cell
death, adhesion, motility,
proliferation, migration,
formation, chemotaxis,
chemokinesis

205166_at

CAPN5

2.693

205355_at

ACADSB

2.242

205513_at

TCN1

2.866

205552_s_at

OAS1

6.225

205636_at

SH3GL3

2.63

SH3-domain GRB2-like 3

206826_at

PMP2

2.229

206830_at

SLC4A10

5.34

207096_at
207128_s_at

SAA4
ZNF223

2.841
2.08

207362_at

SLC30A4

2.264

207449_s_at
207815_at
208026_at

POFUT2
PF4V1
HIST1H4F

2.2
2.933
2.664

peripheral myelin protein 2
solute carrier family 4, sodium
bicarbonate transporter-like,
member 10
serum amyloid A4, constitutive
Zinc finger protein 223
solute carrier family 30 (zinc
transporter), member 4
protein O-fucosyltransferase 2
platelet factor 4 variant 1
histone 1, H4f

acyl-Coenzyme A
dehydrogenase,
short/branched chain
transcobalamin I (vitamin B12
binding protein, R binder
family)
2',5'-oligoadenylate synthetase
1, 40/46kDa

208121_s_at

PTPRO

2.059

protein tyrosine
phosphatase, receptor type,
O

208261_x_at

IFNA10

2.258

interferon, alpha 10

209244_s_at

KIF1C

2.28

kinesin family member 1C

209483_s_at

NSL1

2.049

210198_s_at

PLP1

13.8

210272_at

CYP2B7P1

2.092

NSL1, MIND kinetochore
complex component, homolog
(S. cerevisiae)
proteolipid protein 1
(Pelizaeus-Merzbacher
disease, spastic paraplegia 2,
uncomplicated)
cytochrome P450, family 2,
subfamily B, polypeptide 7
pseudogene 1
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metabolic process

cobalt ion transport
immune response
formation, detachment,
endocytosis, migration
activation, transport
Transport
acute-phase response
regulation of transcription
Transport
metabolic process
immune response
Unknown
apoptosis, growth, cell cycle
progression, survival,
proliferation, presence, cell
movement
defense response
transport, dynamics, depletion,
redistribution, cell viability,
motility
cell cycle; chromosome
segregation; mitosis;
methylation; cell division
synaptic transmission,
depolarization, damage,
proliferation
electron transport

Gene Name

Gene
Symbol

210302_s_at

MAB21L2

R280C
Fold
Change
9.488

210583_at

POLDIP3

2.745

210657_s_at

SEPT4

3.748

septin 4

210661_at

GLRA3

6.111

glycine receptor, alpha 3
mannan-binding lectin serine
peptidase 1 (C4/C2 activating
component of Ra-reactive
factor)

210680_s_at

MASP1

2.002

211141_s_at

CNOT3

2.213

211144_x_at

TRGC2

2.723

211479_s_at

HTR2C

2.833

211718_at

MGC2889

2.439

211907_s_at

PARD6B

5.744

212354_at

SULF1

2.079

213113_s_at

SLC43A3

2.538

213421_x_at

PRSS3

2.204

213802_at

PRSS12

2.106

214411_x_at
214587_at

CTRB2
COL8A1
NY-REN-7 ;
LOC389347

2.349
2.64

214945_at

3.941

215199_at

CALD1

2.716

215231_at

PRKAG2

3.821

215417_at

EXOC6B

2.249

Description

Function

mab-21-like 2 (C. elegans)
polymerase (DNA-directed),
delta interacting protein 3

nervous system development

CCR4-NOT transcription
complex, subunit 3
T cell receptor gamma
constant 2
5-hydroxytryptamine
(serotonin) receptor 2C
hypothetical protein MGC2889
par-6 partitioning defective 6
homolog beta (C. elegans)
sulfatase 1
solute carrier family 43,
member 3
protease, serine, 3
(mesotrypsin)
Protease, serine, 12
(neurotrypsin, motopsin)
chymotrypsinogen B2
collagen, type VIII, alpha 1
NY-REN-7 antigen ; similar to
KIAA0752 protein

caldesmon 1

Protein kinase, AMP-activated,
gamma 2 non-catalytic subunit
exocyst complex component
6B
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Unknown
cell death, development,
capacitation, apoptosis
Unknown
complement activation,
classical pathway; innate
immune response
DNA-dependent; regulation of
transcription
immune response
transformation, aggregation,
formation
Unknown
reassembly, polarization,
assembly, structure,
development, transformation,
migration
Apoptosis
Transport
migration, desensitization
migration, desensitization
Proteolysis
Proliferation
Translation
formation, assembly,
cytokinesis, morphology,
translocation, cell cycle
progression, G2/M phase
transition, size, cell movement
fatty acid synthesis
protein transport

Gene Name

Gene
Symbol

R280C
Fold
Change

Description

215430_at

GK2

3.697

glycerol kinase 2

215659_at

GSDML

2.154

Gasdermin-like

glycerol-3-phosphate metabolic
process
Unknown
migration, growth, apoptosis,
G1 phase, G2/M phase
transition, chemotaxis,
proliferation, differentiation

Function

215671_at

PDE4B

2.928

Phosphodiesterase 4B, cAMPspecific (phosphodiesterase
E4 dunce homolog,
Drosophila)

215674_at

KIAA1659

6.587

KIAA1659 protein

Unknown

ret proto-oncogene (multiple
endocrine neoplasia and
medullary thyroid carcinoma 1,
Hirschsprung disease)

transformation, proliferation,
survival, apoptosis,
differentiation, colony
formation, migration, growth,
scattering, mitogenesis

215771_x_at

RET

4.334

216170_at

EEF1G

4.255

216197_at

ATF7IP

3.027

216545_at

LOC441886

Eukaryotic translation
elongation factor 1 gamma
activating transcription factor 7
interacting protein

translational elongation
regulation of transcription

2.842

similar to Aspartate
aminotransferase,
mitochondrial precursor
(Transaminase A) (Glutamate
oxaloacetate transaminase-2)

Unknown

immunoglobulin heavy
constant alpha 1

proliferation, apoptosis,
phagocytosis, binding, growth,
cytolysis, differentiation,
mitogenesis, infiltration

216557_x_at

IGHA1

2.742

216566_at

IGLC2

5.48

216639_at

SRPX2

2.201

216722_at

VENTXP1

2.21

216895_at

GABRG3

2.018

219115_s_at

IL20RA

3.102

Immunoglobulin lambda
joining 3
sushi-repeat-containing
protein, X-linked 2
VENT homeobox (Xenopus
laevis) pseudogene 1
gamma-aminobutyric acid
(GABA) A receptor, gamma 3
interleukin 20 receptor, alpha

219671_at

HPCAL4

2.066

hippocalcin like 4

219761_at

CLEC1A

2.746

219841_at

AICDA

4.321

219898_at

GPR85

4.489

C-type lectin domain family 1,
member A
activation-induced cytidine
deaminase
G protein-coupled receptor 85
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Unknown
Unknown
Unknown
ion transport
blood coagulation
central nervous system
development
defense response
accumulation, proliferation,
activation
signal transduction

Gene Name

Gene
Symbol

R280C
Fold
Change

219938_s_at

PSTPIP2

4.91

220035_at

NUP210

3.291

220210_at

CHRNA10

2.188

cholinergic receptor, nicotinic,
alpha polypeptide 10

220290_at
220327_at
220623_s_at
221136_at

AIM1L
VGL-3
TSGA10
GDF2

4.425
2.237
2.215
2.269

absent in melanoma 1-like
vestigial-like 3
testis specific, 10
Growth differentiation factor 2

221491_x_at

HLA-DRB1

2.001

major histocompatibility
complex, class II, DR beta 1

221633_at

NCAPH2

2.051

221857_s_at

TJAP1

2.292

222137_at

CC2D1A

2.083

222196_at

LOC286434

2.616

222293_at

IGSF4C

2.034

220673_s_at

KIAA1622

0.372

Description
proline-serine-threonine
phosphatase interacting
protein 2
nucleoporin 210kDa

Non-SMC condensin II
complex, subunit H2
Tight junction associated
protein 1 (peripheral)
Coiled-coil and C2 domain
containing 1A
hypothetical protein
LOC286434
immunoglobulin superfamily,
member 4C
KIAA1622

212486_s_at

FYN

0.498

FYN oncogene related to
SRC, FGR, YES

219263_at

RNF128

0.257

Ring finger protein 128

204268_at

S100A2

0.488

S100 calcium binding protein
A2

219985_at

HS3ST3A1

0.491

205590_at

RASGRP1

0.449

Heparin sulfate
(glucosamine) 3-Osulfotransferase 3A1
RAS guanyl releasing
protein 1 (calcium and DAGregulated)
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Function

Cytokinesis
protein targeting
synaptic transmission,
depolarization, damage,
proliferation
Unknown
regulation of transcription
Spermatogenesis
Proliferation
cell death, proliferation,
apoptosis, adhesion, binding,
activation, inhibition
Segregation
Growth
regulation of transcription
Unknown
immune response
Unknown
proliferation, morphology,
apoptosis, adhesion,
myelination, activation,
migration, development,
degranulation
regulation of transcription
endothelial cell migration,
tumor suppressor,
differentiation
transferase activity
proliferation, maturation,
transformation, migration,
differentiation, apoptosis

Gene Name

Gene
Symbol

R280C
Fold
Change

Description

Function

215719_x_at

FAS

0.444

Fas (TNF receptor
superfamily, member 6)

apoptosis, immune
response, signal
transduction

203066_at

GALNAC4S6ST

0.363

B cell RAG associated protein

hexose biosynthetic process

suppressor of variegation 3-9
homolog 2 (Drosophila)

cell differentiation, chromatin
assembly, regulation of
transcription, cell cycle,
chromatin modification

219262_at

SUV39H2

0.378

202783_at

NNT

0.46

204841_s_at

EEA1

0.474

nicotinamide nucleotide
transhydrogenase
early endosome antigen 1,
162kD

207029_at

KITLG

0.442

KIT ligand

208384_s_at

MID2

0.484

209357_at

CITED2

0.415

209802_at

PHLDA2

0.445

midline 2
Cbp/p300-interacting
transactivator, with Glu/Asprich carboxy-terminal
domain, 2
pleckstrin homology-like
domain, family A, member 2

209910_at

SLC25A16

0.47

210985_s_at

SP100

0.34

213297_at

RMND5B

0.451

213307_at

SHANK2

0.5

213935_at

ABHD5

0.392

solute carrier family 25
(mitochondrial carrier; Graves
disease autoantigen), member
16
nuclear antigen Sp100
equired for meiotic nuclear
division 5 homolog B (S.
cerevisiae)
SH3 and multiple ankyrin
repeat domains 2
abhydrolase domain
containing 5

electron transport
vesicle fusion
proliferation, colony formation,
apoptosis, differentiation,
growth, survival, migration,
degranulation, chemotaxis
Unknown
proliferation, morphology,
apoptosis
Growth

Transport
invasion, migration
Meiosis
intracellular signaling cascade
proteolysis; aromatic
compound metabolic process
transformation, apoptosis, cell
cycle progression, growth, cell
spreading, morphology,
migration, outgrowth

214230_at

CDC42

0.499

cell division cycle 42 (GTP
binding protein, 25kDa)

215095_at

ESD

0.493

Esterase D/formylglutathione
hydrolase

Unknown

215118_s_at

IGHA1

0.444

Translocation associated
fusion protein IRTA1/IGA1
(IRTA1/IGHA1)

immune response

215470_at

GTF2H2

0.498

General transcription factor
IIH, polypeptide 2, 44kDa

regulation of transcription
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Gene Name

Gene
Symbol

R280C
Fold
Change

218309_at

CAMK2N1

0.307

219262_at

SUV39H2

0.378

219263_at

RNF128

0.257

Ring finger protein 128

219973_at

ARSJ

0.485

219985_at

HS3ST3A1

0.491

219999_at

MAN2A2

0.491

220216_at

C8orf44

0.425

220321_s_at

CCDC121

0.458

221350_at

HOXC8

0.367

arylsulfatase J
Heparin sulfate (glucosamine)
3-O-sulfotransferase 3A1
mannosidase, alpha, class 2A,
member 2
chromosome 8 open reading
frame 44
coiled coil domain containing
21
homeo box C8

222180_at

YES1

0.478

Description
Calcium/calmodulindependent protein kinase II
inhibitor 1
suppressor of variegation 3-9
homolog 2 (Drosophila)

V-yes-1 Yamaguchi sarcoma
viral oncogene homolog 1

Function

adhesion, survival
remodeling, length, assembly,
binding, mitosis
ubiquitin cycle; negative
regulation of cytokine
biosynthetic process
Unknown
transferase activity
metabolic process
Unknown
Unknown
regulation of transcription
neuritogenesis, assembly,
disassembly, invasion,
anoikis, transformation,
apoptosis

Table 10: Genes that were specifically regulated by TAp63γ(R280C) mutant alone when
compared to wildtype TAp63γ
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Gene Name

Gene
Symbol

R204W
Fold
Change

Description

Functions

209784_s_at

JAG2

0.453

jagged 2

differentiation, proliferation,
apoptosis, adhesion, survival,
selection

214156_at

MYRIP

0.376

myosin VIIA and Rab
interacting protein

intracellular protein transport
invasion, invasiveness,
aggregation, proliferation,
migration, differentiation,
apoptosis, malignancy,
growth, cell movement
endoplasmic reticulum stress
response

204475_at

MMP1

0.358

matrix metallopeptidase
1 (interstitial
collagenase)

201843_s_at

EFEMP1

0.285

EGF-containing fibulinlike extracellular matrix
protein 1

202438_x_at

IDS

0.382

202871_at

TRAF4

0.387

202895_s_at

SIRPA

iduronate 2-sulfatase
(Hunter syndrome)
TNF receptor-associated
factor 4

metabolic process
colony formation, apoptosis,
growth

0.399

signal-regulatory protein
alpha

adhesion, phagocytosis, cell
spreading, migration, apoptosis,
survival, polarization,
attachment

glycine
amidinotransferase (Larginine:glycine
amidinotransferase)

creatine biosynthetic process

203178_at

GATM

0.493

203563_at

AFAP1

0.284

204840_s_at

EEA1

0.477

204845_s_at

ENPEP

0.434

206268_at

LEFTY1

0.415

206919_at

ELK4

0.148

ELK4, ETS-domain
protein (SRF accessory
protein 1)

regulation of transcription

0.483

major histocompatibility
complex, class II, DR
beta 1

activation, proliferation,
apoptosis, interaction, inhibition,
binding, negative selection,
positive selection, conversion

209312_x_at

HLA-DRB1

actin filament associated
protein
early endosome antigen
1, 162kD
glutamyl aminopeptidase
(aminopeptidase A)
left-right determination
factor 1
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cross-linkage, organization
vesicle fusion
signaling, proliferation, activity
migration, proliferation

Gene Name

Gene
Symbol

R204W
Fold
Change

Description

Functions

209916_at

DHTKD1

0.499

dehydrogenase E1 and
transketolase domain containing 1

metabolic process

210218_s_at

SP100

0.465

nuclear antigen Sp100

invasion, migration

210675_s_at

PTPRR

0.382

protein tyrosine phosphatase,
receptor type, R

Proliferation

211440_x_at

CYP3A43

0.425

cytochrome P450, family 3,
subfamily A, polypeptide 43

electron transport

212394_at
212991_at

KIAA0090
FBXO9

0.494
0.153

KIAA0090
F-box protein 9

protein binding
protein ubiquitination

214600_at

TEAD1

0.404

TEA domain family member 1
(SV40 transcriptional enhancer
factor)

regulation of
transcription

214934_at

ATP9B

0.329

ATPase, Class II, type 9B

Transport

0.493

ABO blood group (transferase A,
alpha 1-3-Nacetylgalactosaminyltransferase;
transferase B, alpha 1-3galactosyltransferase)

metabolic process

216716_at

ABO

217020_at

RARB

0.407

retinoic acid receptor, beta

differentiation, growth,
apoptosis, cell cycle
progression, cytostasis,
morphology,
proliferation

217671_at

RFX3

0.268

Regulatory factor X, 3 (influences
HLA class II expression)

regulation of
transcription

218174_s_at

C10orf57

0.297

chromosome 10 open reading frame
57

Unknown

219334_s_at

OBFC2A

0.5

oligonucleotide/oligosaccharidebinding fold containing 2A

Unknown

219799_s_at

DHRS9

0.479

dehydrogenase/reductase (SDR
family) member 9

metabolic process

219834_at

ALS2CR8

0.441

amyotrophic lateral sclerosis 2
(juvenile) chromosome region,
candidate 8

regulation of
transcription

221874_at

KIAA1324

0.45

KIAA1324

Unknown
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Gene Name

Gene Symbol

R204W
Fold
Change

117_at

HSPA6

5.087

200795_at

SPARCL1

5.095

213418_at

HSPA6

11.85

222153_at

MYEF2

2.056

Description

Functions

heat shock 70kDa protein
6 (HSP70B')

apoptosis, cell death, growth,
cell viability, proliferation,
colony, differentiation,
endoplasmic reticulum stress
response, survival,
condensation

SPARC-like 1 (mast9,
hevin)
heat shock 70kDa protein
6 (HSP70B')
myelin expression factor
2

204932_at

TNFRSF11B

2.434

tumor necrosis factor
receptor superfamily,
member 11b
(osteoprotegerin)

211513_s_at

OGFR

2.628

opioid growth factor
receptor

211753_s_at

RLN1

2.313

relaxin 1

212523_s_at

KIAA0146

2.284

KIAA0146 protein

2.202

Src homology 3 domaincontaining guanine
nucleotide exchange
factor

222121_at

SGEF

Apoptosis
Chaperone
Commitment
apoptosis, differentiation,
osteoclastogenesis,
proliferation, activity,
activation, anoikis, cell
viability
Growth
signal transduction; female
pregnancy
Unknown
signal transduction

Table 11: Genes that were specifically regulated by TAp63γ(R204W) mutant alone when
compared to wildtype TAp63γ
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Gene Name

Gene
Symbol

C306R
Fold
Change

Description

Functions

203989_x_at

F2R

0.45

coagulation factor II
(thrombin) receptor

aggregation, proliferation,
activation, invasion,
morphology, shape change,
transformation, cell cycle
progression, cell movement

209250_at

DEGS1

0.476

degenerative spermatocyte
homolog 1, lipid desaturase
(Drosophila)

growth, sub-G1 phase

215407_s_at

ASTN2

0.183

astrotactin 2

Unknown

203634_s_at

CPT1A

0.333

carnitine palmitoyltransferase 1A
(liver)

cell death

212815_at

ASCC3

0.495

Activating signal cointegrator 1
complex subunit 3

Unknown

214764_at

RRP15

0.467

ribosomal RNA processing 15
homolog (S. cerevisiae)

protein binding

211074_at

FOLR1

0.492

folate receptor 1 (adult) ;
folate receptor 1 (adult)

growth, colony formation,
proliferation, cell viability

209277_at

TFPI2

0.435

Tissue factor pathway inhibitor 2

proliferation, invasion,
attachment

0.483

chondroitin sulfate GalNAcT-2

Unknown

0.496

KIAA0372

Unknown

222235_s_at
203049_s_at

GALNACT2
KIAA0372

210495_x_at

FN1

0.467

fibronectin 1

migration, adhesion, cell
spreading, apoptosis,
proliferation, attachment,
assembly, survival

221765_at

UGCG

0.468

UDP-glucose ceramide
glucosyltransferase

epidermis development,
biosynthetic process

221841_s_at

KLF4

0.452

Kruppel-like factor 4 (gut)

proliferation, migration, colony
formation, invasion, cell cycle
progression, growth, size,
morphology, amplification

204925_at

CTNS

0.441

cystinosis, nephropathic

Transport

212538_at

DOCK9

0.468

dedicator of cytokinesis 9

Unknown
growth, apoptosis, signaling,
rotation, survival,
invasiveness, cell viability,
morphology, G1 phase
Binding, apoptosis

221577_x_at

GDF15

0.377

growth differentiation factor
15

210466_s_at

SERBP1

0.469

SERPINE1 mRNA binding
protein 1
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Gene Name

Gene
Symbol

C306R
Fold
Change

Description

Functions

209676_at

TFPI

0.349

tissue factor pathway inhibitor
(lipoprotein-associated
coagulation inhibitor)

blood coagulation

201213_at

PPP1R7

0.351

202848_s_at

GRK6

0.467

203875_at

SMARCA1

0.354

208661_s_at

TTC3

0.479

221766_s_at

FAM46A

0.492

212079_s_at

MLL

0.462

60474_at

C20orf42

0.394

209712_at

SLC35D1

0.445

protein phosphatase 1,
regulatory subunit 7
G protein-coupled receptor
kinase 6
SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin, subfamily
a, member 1
tetratricopeptide repeat domain
3
family with sequence similarity
46, member A
Myeloid/lymphoid or mixedlineage leukemia (trithorax
homolog, Drosophila)
chromosome 20 open reading
frame 42
solute carrier family 35 (UDPglucuronic acid/UDP-Nacetylgalactosamine dual
transporter), member D1

203216_s_at

MYO6

0.344

myosin VI

212984_at

ATF2

0.432

Activating transcription factor
2

202284_s_at

CDKN1A

0.469

cyclin-dependent kinase inhibitor
1A (p21, Cip1)

205370_x_at

DBT

0.466

dihydrolipoamide branched
chain transacylase E2

201141_at

GPNMB

0.415

201200_at

CREG1

0.398

glycoprotein (transmembrane)
nmb
Cellular repressor of E1Astimulated genes 1
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Unknown
chemotaxis, influx, migration
remodeling, differentiation,
outgrowth
Unknown
Unknown
transformation, growth,
differentiation, colony
formation, immortalization,
apoptosis, maturation, selfrenewal, development,
proliferation
Unknown

Transport
differentiation, apoptosis,
plasticity, morphogenesis,
integrity, DNA damage
response
growth, differentiation,
colony formation, cell death,
G2/M phase transition,
survival, synaptic
transmission, recovery,
double-stranded DNA break
repair
apoptosis, growth, proliferation,
cell cycle progression, G1
phase, cell death, senescence,
differentiation, S phase, G2
phase
metabolic process
adhesion, proliferation
growth, differentiation, G1/S
phase transition, proliferation

Gene Name

Gene
Symbol

C306R
Fold
Change

201299_s_at

MOBK1B

0.478

201534_s_at

UBL3

0.447

Description
MOB1, Mps One Binder kinase
activator-like 1B (yeast)
ubiquitin-like 3

Functions
Telophase
protein modification process

201617_x_at

CALD1

0.457

caldesmon 1

assembly, cytokinesis,
morphology, translocation, cell
cycle progression, G2/M phase
transition, size, cell movement

201939_at

PLK2

0.486

polo-like kinase 2 (Drosophila)

apoptosis, growth, S phase,
survival

202127_at

PRPF4B

0.351

PRP4 pre-mRNA processing
factor 4 homolog B (yeast)

mRNA processing
adhesion, binding, migration,
invasion, proliferation,
apoptosis, growth, motility,
survival, cell spreading
binding, deformation,
morphology, biogenesis

202351_at

ITGAV

0.476

integrin, alpha V (vitronectin
receptor, alpha polypeptide,
antigen CD51)

202890_at

MAP7

0.425

microtubule-associated protein 7

203049_s_at

KIAA0372

0.496

KIAA0372

203078_at

CUL2

0.327

cullin 2

203455_s_at

SAT1

0.458

203671_at

TPMT

0.423

spermidine/spermine N1acetyltransferase
Thiopurine S-methyltransferase
Inositol 1,4,5-triphosphate
receptor, type 1

203710_at

ITPR1

0.339

204056_s_at

MVK

0.44

204184_s_at

ADRBK2

0.491

204545_at

PEX6

0.343

mevalonate kinase (mevalonic
aciduria)
Adrenergic, beta, receptor
kinase 2
peroxisomal biogenesis factor 6

204761_at

USP6NL

0.496

USP6 N-terminal like

204793_at

GPRASP1

0.414

204821_at

BTN3A3

0.373

204970_s_at

MAFG

0.436

G protein-coupled receptor
associated sorting protein 1
butyrophilin, subfamily 3,
member A3
v-maf musculoaponeurotic
fibrosarcoma oncogene homolog
G (avian)
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Unknown
G1/S phase transition,
proliferation, cell cycle
progression, growth,
apoptosis
growth, cytostasis, apoptosis
Proliferation
apoptosis, release, leakage,
cell death, calcium oscillation,
depolarization, extension, long
term depression
biosynthetic process
Mitogenesis
Biogenesis
regulation of Rab GTPase
activity
Unknown
Unknown
proliferation, dysfunction,
differentiation

Gene Name

Gene
Symbol

C306R
Fold
Change

205575_at

C1QL1

0.432

206141_at
206440_at
206526_at

MOCS3
LIN7A
RIBC2

0.288
0.487
0.488

206613_s_at

TAF1A

0.454

206857_s_at

FKBP1B

0.36

206942_s_at

PMCH

0.451

207143_at

CDK6

0.417

207455_at

P2RY1

0.259

207565_s_at

MR1

0.483

Description
complement component 1, q
subcomponent-like 1
molybdenum cofactor synthesis 3
lin-7 homolog A (C. elegans)
RIB43A domain with coiled-coils 2
TATA box binding protein (TBP)associated factor, RNA polymerase
I, A, 48kDa
FK506 binding protein 1B, 12.6
kDa
pro-melanin-concentrating
hormone

Cyclin-dependent kinase 6

Purinergic receptor P2Y, G-protein
coupled, 1
Major histocompatibility complex,
class I-related

Functions
Unknown
Unknown
Transport
Unknown
regulation of transcription
proliferation, cell viability
hyperpolarization, plasticity
cell cycle progression, G1
phase, G1/S phase
transition, proliferation,
growth, transformation,
apoptosis, checkpoint
control, lifespan
aggregation, binding
antigen processing
stability, sister chromatid
exchange, exchange,
aberration, cell death,
aneuploid, growth, apoptosis,
survival
cell rounding, survival,
apoptosis, growth,
decondensation, assembly,
transformation, proliferation

207598_x_at

XRCC2

0.489

X-ray repair complementing
defective repair in Chinese hamster
cells 2

208325_s_at

AKAP13

0.397

A kinase (PRKA) anchor protein 13

208806_at

CHD3

0.337

chromodomain helicase DNA
binding protein 3

209016_s_at

KRT7

0.467

keratin 7

transmembrane potential,
endoplasmic reticulum stress
response, lysis, activation,
replication

remodeling, assembly,
biogenesis
cytoskeleton organization
and biogenesis

209040_s_at

PSMB8

0.399

proteasome (prosome, macropain)
subunit, beta type, 8 (large
multifunctional peptidase 7)

209119_x_at

NR2F2

0.5

Nuclear receptor subfamily 2,
group F, member 2

Migration

transforming growth factor, beta
2

proliferation, apoptosis,
growth, differentiation,
cytostasis, cell cycle
progression, cell death,
colony formation,
adhesion, stimulation

209909_s_at

TGFB2

0.486
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Gene Name

Gene Symbol

C306R
Fold
Change

Description

Functions

210268_at

NFX1

0.38

nuclear transcription factor,
X-box binding 1

Unknown

210655_s_at

FOXO3A

0.414

forkhead box O3A

apoptosis, cell cycle
progression, proliferation,
survival, cell death, DNA
damage response,
checkpoint control,
accumulation, morphology,
transformation

210867_at

CNOT4

0.347

CCR4-NOT transcription
complex, subunit 4

regulation of transcription

phosphoinositide-3-kinase,
regulatory subunit 3 (p55,
gamma)

apoptosis, survival,
proliferation, growth,
morphology, chemotaxis,
cell spreading, cell cycle
progression, S phase,
haptotaxis

211580_s_at

PIK3R3

0.343

211673_s_at

MOCS1

0.472

211828_s_at

TNIK

0.464

211965_at

ZFP36L1

0.444

212310_at

MIA3

0.339

212315_s_at

NUP210

0.276

molybdenum cofactor
synthesis 1
TRAF2 and NCK interacting
kinase
zinc finger protein 36, C3H
type-like 1
melanoma inhibitory activity
family, member 3
nucleoporin 210kDa

212325_at

DKFZP686A01247

0.283

hypothetical protein

Unknown

212930_at

ATP2B1

0.328

ATPase, Ca++ transporting,
plasma membrane 1

proliferation, cell cycle
progression, extension, cell
death

213353_at

ABCA5

0.445

213572_s_at

SERPINB1

0.384

213900_at

C9orf61

0.466

214130_s_at

PDE4DIP

0.375

214330_at

ATPAF2

0.468

ATP-binding cassette, subfamily A (ABC1), member 5
serpin peptidase inhibitor,
clade B (ovalbumin), member
1
chromosome 9 open reading
frame 61
phosphodiesterase 4D
interacting protein
(myomegalin)
ATP synthase mitochondrial
F1 complex assembly factor
2
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metabolic process
cell spreading
Proliferation
Unknown
cell viability

Transport
Unknown
Unknown
cytoskeleton organization
and biogenesis
protein folding

Gene Name

Gene
Symbol

C306R
Fold
Change

Description

214724_at

DIXDC1

0.443

DIX domain containing 1

214993_at

ASPHD1

0.471

215030_at

GRSF1

0.437

215069_at

NMT2

0.429

215150_at

YOD1

0.485

aspartate beta-hydroxylase
domain containing 1
G-rich RNA sequence binding
factor 1
N-myristoyltransferase 2
YOD1 OTU deubiquinating
enzyme 1 homolog ( yeast)

Functions
multicellular organismal
development
peptidyl-amino acid
modification
morphogenesis of embryonic
epithelium
Binding
ubiquitin cycle
adhesion, apoptosis,
recognition, attachment, cell
movement, growth,
proliferation, elastogenesis,
differentiation, outgrowth

215646_s_at

VCAN

0.246

versican

215886_x_at

USP12

0.47

ubiquitin specific peptidase 12

Unknown

216218_s_at

PLCL2

0.409

phospholipase C-like 2

binding, activation,
hyperproliferation, migration,
development, signaling,
apoptosis

216531_at

MBTPS2 ;
YY2

0.355

membrane-bound transcription
factor peptidase, site 2 ; YY2
transcription factor

Unknown

216841_s_at

SOD2

0.392

superoxide dismutase 2,
mitochondrial

apoptosis, cell death,
proliferation, transmembrane
potential, survival, growth,
mitogenesis, response,
migration

216962_at

OR5T2
RPAIN

0.399

RPA interacting protein
olfactory receptor, family 5,
subfamily T, member 2

signal transduction
growth, apoptosis,
transformation, cell death, cell
cycle progression, binding,
shunting, morphology,
differentiation

217607_x_at

EIF4G2

0.433

eukaryotic translation initiation
factor 4 gamma, 2

218031_s_at

FOXN3

0.495

forkhead box N3

218166_s_at

RSF1

0.5

remodeling and spacing factor 1

218183_at

C16orf5

0.44

218502_s_at

TRPS1

0.388

218935_at

EHD3

0.455

219012_s_at

C11orf30

0.318

chromosome 16 open reading
frame 5
trichorhinophalangeal syndrome
I
EH-domain containing 3
chromosome 11 open reading
frame 30
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G2/M phase
positioning, assembly,
remodeling
Unknown
Apoptosis
Unknown
DNA repair

Gene Name

Gene
Symbol

219094_at

ARMC8

C306R
Fold
Change
0.437

219174_at

IFT74

0.414

219274_at

TSPAN12

0.413

219346_at

LRFN3

0.428

219387_at

CCDC88A

0.465

coiled-coil domain containing 88A

219460_s_at

TMEM127

0.307

219499_at

SEC61A2

0.466

220039_s_at

CDKAL1

0.496

220474_at

SLC25A21

0.286

220764_at

PPP4R2

0.347

220776_at

KCNJ14

0.344

220940_at
221683_s_at
221276_s_at

KIAA1641
Cep290
SYNC1
NACA ;
NACAP1

0.421
0.386
0.431

222031_at

LOC286434

0.449

222263_at

SLC35E1

0.49

51228_at

RBM12B

0.475

204697_s_at

CHGA

3.233

transmembrane protein 127
Sec61 alpha 2 subunit (S.
cerevisiae)
CDK5 regulatory subunit
associated protein 1-like 1
solute carrier family 25
(mitochondrial oxodicarboxylate
carrier), member 21
protein phosphatase 4, regulatory
subunit 2
potassium inwardly-rectifying
channel, subfamily J, member 14
KIAA1641
centrosome protein cep290
Syncoilin, intermediate filament 1
Nascent-polypeptide-associated
complex alpha polypeptide
hypothetical protein LOC286434 ;
similar to Serine/threonine-protein
kinase PRKX (Protein kinase
PKX1)
solute carrier family 35, member
E1
RNA binding motif protein 12B
chromogranin A (parathyroid
secretory protein 1)

204777_s_at

MAL

3.067

mal, T-cell differentiation protein

214974_x_at

CXCL5

17.62

chemokine (C-X-C motif) ligand 5

219080_s_at

CTPS2

2.818

204770_at

TAP2

2.569

212806_at

KIAA0367

6.454

CTP synthase II
transporter 2, ATP-binding
cassette, sub-family B
(MDR/TAP)
KIAA0367

222018_at

0.394

Description

Functions

armadillo repeat containing 8
ntraflagellar transport 74 homolog
(Chlamydomonas)
tetraspanin 12
leucine rich repeat and fibronectin
type III domain containing 3

Unknown
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Unknown
Unknown
Unknown
proliferation, migration,
replication, phosphorylation,
biogenesis
Unknown
protein transport
metabolic process
Transport
protein modification process
hyperpolarization, plasticity
Unknown
Unknown
Unknown
transport, transcription,
translation
Unknown

Transport
Unknown
Activation, injury, biogenesis
polarization, development,
differentiation
chemotaxis, transmigration,
signaling, stimulation,
proliferation, activation
Unknown
Segregation
Apoptosis

Description

Functions

TRAF3IP2

C306R
Fold
Change
2.297

TRAF3 interacting protein 2

203741_s_at

ADCY7

2.294

adenylate cyclase 7

Apoptosis
growth, apoptosis, G1 phase,
G2/M phase transition

204276_at

TK2

2.35

thymidine kinase 2,
mitochondrial

Gene Name

Gene
Symbol

202987_at

Transformation
proliferation, migration,
angiogenesis, invasion,
signaling, volume, cell death,
differentiation
fasciculation, lamination, longterm potentiation,
development, adhesion,
morphology

205110_s_at

FGF13

2.036

fibroblast growth factor 13

205669_at

NCAM2

3.577

neural cell adhesion molecule 2

206094_x_at

UGT1A6

2.377

206181_at

SLAMF1

2.467

210176_at

TLR1

2.256

UDP glucuronosyltransferase 1
family, polypeptide A6
Signaling lymphocytic activation
molecule family member 1
toll-like receptor 1

210969_at

PKN2

3.023

protein kinase N2

apoptosis, cell-cell adhesion,
differentiation, reorganization

210999_s_at

GRB10

2.262

growth factor receptor-bound
protein 10

growth, apoptosis,
transformation, G2 phase, S
phase, signaling

211315_s_at

CACNA1G

2.372

212425_at

SCAMP1

2.024

213382_at

MST1

12.32

215783_s_at

ALPL

2.163

215844_at

TNPO2

3.063

216077_s_at

L3MBTL

2.029

216565_x_at

LOC391020

2.054

218468_s_at

GREM1

2.552

219501_at

ENOX1

2.191

calcium channel, voltagedependent, alpha 1G subunit
Secretory carrier membrane
protein 1
macrophage stimulating 1
(hepatocyte growth factor-like)
alkaline phosphatase,
liver/bone/kidney
transportin 2 (importin 3,
karyopherin beta 2b)
l(3)mbt-like (Drosophila)
similar to Interferon-induced
transmembrane protein 3
(Interferon-inducible protein 18U)
gremlin 1, cysteine knot
superfamily, homolog (Xenopus
laevis)
ecto-NOX disulfide-thiol
exchanger 1
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metabolic process
proliferation, co-stimulation,
activation, polarization
inflammatory response

proliferation, neuritogenesis,
cell death
Transport
migration, growth, morphology,
scattering, stimulation, motility,
activation, atrophy
Mineralization
Transport
Cytokinesis
Unknown

signaling, growth, migration
Unknown

Gene Name

Gene
Symbol

C306R
Fold
Change

220115_s_at

CDH10

2.817

220591_s_at

EFHC2

2.039

220686_s_at

PIWIL2

3.347

piwi-like 2 (Drosophila)

221169_s_at

HRH4

2.246

histamine receptor H4

Description
cadherin 10, type 2 (T2cadherin)
EF-hand domain (C-terminal)
containing 2

Functions
cell-cell adhesion
Unknown
zygotene, prophase, early
pachytene stage, development
binding, chemotaxis

Table 12: Genes that were specifically regulated by TAp63γ(C306R) mutant alone when
compared to wildtype TAp63γ
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Gene Name

Gene
Symbol

R279H
Fold
Change

Description

Functions

206763_at

FKBP6

2.303

FK506 binding protein 6, 36kDa

misalignment,
homologous pairing

222313_at

CNOT2

2.197

CCR4-NOT transcription
complex, subunit 2

Growth

carcinoembryonic antigen-related
cell adhesion molecule 5

aggregation, binding,
colony formation,
cytotoxicity, stimulation,
differentiation, activation,
anoikis

collagen, type I, alpha 1

aggregation, migration,
proliferation, binding,
adhesion, morphology,
invasion, cell spreading,
degranulation, growth

201884_at

CEACAM5

2.381

202311_s_at

COL1A1

3.253

208142_at

FAM12A

3.16

219945_at

DDX25

2.455

215457_at

205625_s_at

215723_s_at

ARPC1A

CALB1

PLD1

family with sequence similarity
12, member A
DEAD (Asp-Glu-Ala-Asp) box
polypeptide 25

Unknown
Spermatogenesis

Actin related protein 2/3 complex,
subunit 1A, 41kDa

polymerization, assembly,
nucleation, organization,
stabilization, polarization,
rearrangement, biogenesis

6.805

calbindin 1, 28kDa

apoptosis, cytotoxic
reaction, survival,
paired-pulse facilitation,
function, fragmentation,
plasticity

2.306

phospholipase D1,
phophatidylcholine-specific

fusion, migration, invasion,
size, attachment,
elongation, cell flattening,
morphology, budding

thioredoxin interacting protein

proliferation, apoptosis,
survival, sub-G1 phase,
development, growth,
activity, response,
differentiation

3.09

201010_s_at

TXNIP

2.03

202157_s_at

CUGBP2

2.115

202546_at

VAMP8

2.237

CUG triplet repeat, RNA binding
protein 2
vesicle-associated membrane
protein 8 (endobrevin)
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Unknown
exocytosis, secretion,
fusion, growth

Description

Functions

TFIP11

R279H
Fold
Change
2.292

tuftelin interacting protein 11

Unknown

203231_s_at

ATXN1

5.369

ataxin 1

vacuolation, loss, synaptic
transmission, morphology,
apoptosis

203240_at

FCGBP

2.114

203698_s_at

FRZB

3.597

Fc fragment of IgG binding
protein
frizzled-related protein

203962_s_at

NEBL

2.875

nebulette

203969_at

LOC153914

2.326

hypothetical protein LOC153914

204008_at

DNAL4

2.011

204124_at

SLC34A2

3.131

204310_s_at

NPR2

2.654

natriuretic peptide receptor B

intracellular signaling
cascade

204719_at

ABCA8

2.811

ATP-binding cassette, sub-family
A (ABC1), member 8

Transport

205285_s_at

FYB

2.742

FYN binding protein (FYB120/130)

proliferation, binding,
adhesion, migration,
activation

205431_s_at

BMP5

3.23

bone morphogenetic protein 5

205668_at

LY75

2.073

lymphocyte antigen 75

205681_at

BCL2A1

2.288

BCL2-related protein A1

Gene Name

Gene
Symbol

202751_at

dynein, axonemal, light
polypeptide 4
solute carrier family 34 (sodium
phosphate), member 2

immune response
Growth
ion transport; regulation of
actin filament length
Unknown
microtubule motor activity
transmembrane potential

differentiation,
neurogenesis, apoptosis,
cell viability
immune response
apoptosis, survival,
transformation, cell
death, growth, cell cycle
progression, necrosis,
proliferation, cell
viability

205923_at

RELN

2.515

reelin

migration, positioning,
morphogenesis, positive
selection, compaction,
detachment, branching,
binding

206198_s_at

CEACAM7

2.422

carcinoembryonic antigenrelated cell adhesion molecule 7

Unknown

206331_at

CALCRL

2.55

calcitonin receptor-like

proliferation, migration,
activation, binding,
apoptosis
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Gene Name

Gene
Symbol

R279H
Fold
Change

206420_at

IGSF6

2.981

206609_at
206733_at

MAGEC1
TULP2

2.372
2.086

207056_s_at

SLC4A8

3.099

207175_at

ADIPOQ

2.693

207526_s_at

IL1RL1

3.556

207638_at

PRSS7

2.75

207820_at

ADH1A

2.069

208057_s_at

GLI2

3.3

208154_at

LOC51336

2.276

208245_at

RAB9P1

2.351

209696_at

FBP1

209763_at

CHRDL1

210602_s_at

CDH6

Description
immunoglobulin superfamily,
member 6
melanoma antigen family C, 1
tubby like protein 2
solute carrier family 4, sodium
bicarbonate cotransporter,
member 8

Functions
immune response
unknown
visual perception
ion transport

adiponectin, C1Q and collagen
domain containing

proliferation, migration,
differentiation, colony
formation, binding,
apoptosis, generation, size

interleukin 1 receptor-like 1

activation, differentiation,
proliferation, volume,
infiltration, growth,
recruitment, apoptosis

protease, serine, 7
(enterokinase)
alcohol dehydrogenase 1A (class
I), alpha polypeptide

GLI-Kruppel family member
GLI2

proteolysis
metabolic process
proliferation,
differentiation,
transformation,
development, clustering,
projection, cell death,
branching
morphogenesis

2.877

mesenchymal stem cell protein
DSCD28
RAB9, member RAS oncogene
family, pseudogene 1
fructose-1,6-bisphosphatase 1

metabolic process

2.387

chordin-like 1

differentiation, commitment

cadherin 6, type 2, K-cadherin
(fetal kidney)

adhesion, interaction,
organization, dissociation,
shape change,
segregation, binding,
outgrowth, assembly

3.193
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unknown
unknown

Gene Name

Gene Symbol

R279H
Fold
Change

Description

Functions

210814_at

TRPC3

2.332

transient receptor potential
cation channel, subfamily C,
member 3

transmembrane
potential, binding

211184_s_at

USH1C

2.121

211239_s_at

ADAM7

8.023

211349_at

SLC15A1

2.524

211621_at

AR

2.075

Usher syndrome 1C
(autosomal recessive, severe)
ADAM metallopeptidase
domain 7
solute carrier family 15
(oligopeptide transporter),
member 1
androgen receptor
(dihydrotestosterone
receptor; testicular
feminization; spinal and
bulbar muscular atrophy;
Kennedy disease)

function, differentiation
Proteolysis
oligopeptide transport
growth, proliferation,
apoptosis, migration,
binding, invasion, cell
death, mitogenesis,
cell cycle progression

211825_s_at

FLI1

2.638

Friend leukemia virus
integration 1

growth, apoptosis,
colony formation,
differentiation,
transformation,
morphology, proliferation

212705_x_at

PNPLA2

2.349

patatin-like phospholipase
domain containing 2

metabolic process

213130_at

ZNF473

2.235

zinc finger protein 473

213725_x_at

XYLTI1

4.039

xylosyltransferase I

213866_at

SAMD14

2.416

215151_at

DOCK10

6.949

sterile alpha motif domain
containing 14
dedicator of cytokinesis 10

215591_at

SATB2

2.327

SATB family member 2

215754_at

SCARB2

2.192

scavenger receptor class B,
member 2

cell adhesion

216489_at

TRPM3

2.368

transient receptor potential
cation channel, subfamily M,
member 3

ion transport

216874_at

DKFZp686O1327

2.049

217315_s_at
217525_at

KLK13
OLFML1

2.055
5.858

218029_at

FAM65A

2.08

Homo sapiens, clone
IMAGE:5538654, mRNA
kallikrein 13
olfactomedin-like 1
family with sequence
similarity 65, member A
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regulation of
transcription
glycosaminoglycan
biosynthetic process
Unknown
Unknown
regulation of
transcription

Unknown
Proteolysis
Unknown
DNA directed RNA
polymerase activity

Gene Name

Gene
Symbol

218747_s_at
219044_at

TAPBPL
FLJ10916

R279H
Fold
Change
2.456
2.108

219278_at

MAP3K6

3.279

219945_at

DDX25

2.455

220002_at

KIF26B

4.157

kinesin family member 26B

220336_s_at

GP6

2.021

glycoprotein VI (platelet)

220803_at

AMSH-LP

5.725

Associated molecule with the
SH3 domain of STAM (AMSH)
like protein

221304_at

UGT1A10

2.264

221319_at

PCDHB8

3.59

222128_at

NSUN6

3.023

222168_at

ALDH1A3

2.991

48031_r_at

C5orf4

2.279

56748_at
61297_at

TRIM10
CASKIN2

2.169
2.304

204580_at

MMP12

0.359

matrix metallopeptidase 12
(macrophage elastase)

206650_at

IQCC

0.355

IQ motif containing C

207595_s_at

BMP1

0.448

bone morphogenetic protein 1

210141_s_at

INHA

0.484

inhibin, alpha

218589_at

P2RY5

0.18

37802_r_at

FAM63B

0.246

Description

Functions

TAP binding protein-like
hypothetical protein FLJ10916
mitogen-activated protein kinase
kinase kinase 6
DEAD (Asp-Glu-Ala-Asp) box
polypeptide 25

antigen processing
metabolic process

UDP glucuronosyltransferase 1
family, polypeptide A10
protocadherin beta 8
NOL1/NOP2/Sun domain family,
member 6
Aldehyde dehydrogenase 1
family, member A3
chromosome 5 open reading
frame 4
tripartite motif-containing 10
CASK interacting protein 2

purinergic receptor P2Y, Gprotein coupled, 5
family with sequence similarity
63, member B

Unknown
Spermatogenesis
microtubule-based
movement
aggregation, activation,
adhesion, binding,
inhibition, secretion
ubiquitin cycle
metabolic process
cell adhesion
Unknown
Apoptosis
metabolic process
Hemopoiesis
Unknown
invasion, proliferation,
binding, growth,
recovery, migration,
malignancy
Unknown
differentiation,
neurogenesis, growth
proliferation, necrosis,
stimulation,
differentiation, growth,
signaling
signal transduction
Transport

Table 13: Genes that were regulated specifically by TAp63γ(R279H) mutant alone when
compared to wildtype TAp63γ
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Gene Name

Gene
Symbol

220149_at

FLJ22671

R227Q
Fold
Change
0.448

220119_at

EPB41L4A

0.241

220073_s_at

PLEKHG6

0.434

202057_at

KPNA1

0.476

202463_s_at

MBD3

0.462

Description

Functions

hypothetical protein FLJ22671
erythrocyte membrane protein
band 4.1 like 4A

unknown

pleckstrin homology domain
containing, family G (with
RhoGef domain) member 6
karyopherin alpha 1 (importin
alpha 5)
methyl-CpG binding domain
protein 3

unknown
regulation of transcription
binding, apoptosis
growth

203749_s_at

RARA

0.488

retinoic acid receptor, alpha

differentiation, apoptosis,
maturation, growth,
proliferation, expansion,
endoplasmic reticulum
stress response

204182_s_at

ZBTB43

0.199

zinc finger and BTB domain
containing 43

regulation of transcription

neurotransmission

204230_s_at

SLC17A7

0.4

solute carrier family 17
(sodium-dependent inorganic
phosphate cotransporter),
member 7

205547_s_at

TAGLN

0.256

transgelin

206776_x_at

ACRV1

0.434

acrosomal vesicle protein 1

206971_at

GPR161

0.287

207101_at

VAMP1

0.467

207597_at

ADAM18

0.37

G protein-coupled receptor 161
vesicle-associated membrane
protein 1 (synaptobrevin 1)
ADAM metallopeptidase
domain 18

208349_at

TRPA1

0.483

209293_x_at

ID4

0.349

209859_at

TRIM9

0.428

inhibitor of DNA binding 4,
dominant negative helix-loophelix protein
tripartite motif-containing 9

210150_s_at

LAMA5

0.475

laminin, alpha 5

transient receptor potential
cation channel, subfamily A,
member 1
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invasiveness, biogenesis
multicellular organismal
development
proliferation, migration
Exocytosis, transport
proliferation, migration
ion transport
proliferation, differentiation,
colony formation, survival
unknown
migration, proliferation,
growth, adhesion,
elongation, apoptosis, cell
spreading, invasion,
morphology

Gene Name

Gene
Symbol

210876_at

ANXA2P1

R227Q
Fold
Change
0.337

212636_at

QKI

0.359

214664_at

PAICS

0.335

phosphoribosylaminoimidazole
succinocarboxamide synthetase

purine biosynthesis

215512_at

MARCH6

0.418

membrane-associated ring
finger (C3HC4) 6

ubiquitin cycle

215930_s_at

CTAGE5

0.498

CTAGE family, member 5

enzyme activator activity

216180_s_at

SYNJ2

0.473

synaptojanin 2

Clustering

218800_at

SRD5A2L

0.447

steroid 5 alpha-reductase 2-like

Unknown

221978_at

HLA-F

0.431

207754_at

RASSF8

2.013

215855_s_at

TMF1

2.382

217519_at

MACF1

3.232

Glycine-rich protein (GRP3S)

201187_s_at

ITPR3

2.515

inositol 1,4,5-triphosphate
receptor, type 3

201667_at

GJA1

2.141

gap junction protein, alpha 1,
43kDa (connexin 43)

signaling, proliferation, growth,
apoptosis, assembly, contact
growth inhibition, response

202046_s_at

GRLF1

2.235

glucocorticoid receptor DNA
binding factor 1

neuritogenesis, shape
change, morphology,
development

204530_s_at

TOX

3.08

204920_at

CPS1

2.197

209936_at

RBM5

3.167

RNA binding motif protein 5

apoptosis, proliferation, growth

210755_at

HGF

2.519

hepatocyte growth factor
(hepapoietin A; scatter factor)

migration, proliferation,
apoptosis, invasion, growth,
morphogenesis

Description

Functions

Annexin A2 pseudogene 1
quaking homolog, KH domain
RNA binding (mouse)

unknown

major histocompatibility
complex, class I, F
Ras association (RalGDS/AF-6)
domain family 8
TATA element modulatory
factor 1

thymus high mobility group box
protein TOX
carbamoyl-phosphate
synthetase 1, mitochondrial
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apoptosis, differentiation

immune response
signal transduction
regulation of transcription
depolymerization, stabilization,
stability, cell movement
depolarization, extension,
apoptosis, release

regulation of transcription
metabolic process

Gene Name

Gene
Symbol

R227Q
Fold
Change

212093_s_at

MTUS1

2.199

213056_at

FRMD4B

2.007

215064_at

SC5DL

2.23

215538_at

LARGE

4.537

216740_at

TRERF1

2.644

Description
mitochondrial tumor
suppressor 1
FERM domain containing 4B
Sterol-C5-desaturase (ERG3
delta-5-desaturase homolog,
fungal)-like
like-glycosyltransferase
Transcriptional regulating factor
1

Functions
Proliferation
Unknown
metabolic process
Unknown
regulation of transcription

Table 14: Genes that were specifically regulated by TAp63γ(R227Q) mutant alone when
compared to wildtype TAp63γ
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Gene Name

Gene
Symbol

R298Q
Fold
Change

Description

Functions
single-stranded DNA break
repair, cytostasis, DNA
damage response,
recognition

205060_at

PARG

0.496

poly (ADP-ribose)
glycohydrolase

212392_s_at

PDE4DIP

0.401

phosphodiesterase 4D
interacting protein (myomegalin)

cytoskeleton organization
and biogenesis

214152_at
222227_at

CCPG1
ZNF236

0.453
0.488

cell cycle progression 1
zinc finger protein 236

203570_at

LOXL1

0.349

lysyl oxidase-like 1

Unknown
regulation of transcription
colony formation, cell
death, development

204909_at

DDX6

0.473

DEAD (Asp-Glu-Ala-Asp) box
polypeptide 6

Unknown

205554_s_at

DNASE1L3

0.396

deoxyribonuclease I-like 3

Survival

205647_at

RAD52

0.33

RAD52 homolog (S. cerevisiae)

homologous recombination
repair, development

206214_at

PLA2G7

0.42

206573_at

KCNQ3

0.346

207323_s_at

MBP

0.451

phospholipase A2, group VII
(platelet-activating factor
acetylhydrolase, plasma)
potassium voltage-gated
channel, KQT-like subfamily,
member 3

myelin basic protein

fertilization, motility,
infiltration, apoptosis
Hyperpolarization
activation, proliferation,
stimulation, outgrowth,
priming, infiltration,
myelination, development,
organization, stability
budding, tubulation, motility,
differentiation, sprouting,
migration, commitment,
proliferation, chemotaxis
activation, apoptosis,
proliferation, stimulation,
differentiation, growth,
survival, adhesion,
response

207401_at

PROX1

0.489

prospero-related homeobox 1

208200_at

IL1A

0.498

interleukin 1, alpha

208741_at

SAP18

0.481

sin3-associated polypeptide,
18kDa

cell death

210347_s_at

BCL11A

0.499

B-cell CLL/lymphoma 11A
(zinc finger protein)

apoptosis, transformation,
cell death, differentiation,
growth
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Gene Name

Gene
Symbol

212477_at

CENTB2

R298Q
Fold
Change
0.486

213849_s_at

PPP2R2B

0.493

214291_at

RPL17

0.469

214668_at

C13orf1

0.469

217127_at

CTH

0.464

218901_at
219509_at

PLSCR4
MYOZ1

0.495
0.424

219694_at

FAM105A

0.486

219747_at

C4orf31

0.34

221016_s_at

TCF7L1

0.31

36612_at

KIAA0280

0.471

205817_at

SIX1

2.828

sine oculis homeobox homolog
1 (Drosophila)

219996_at

ASB7

2.06

Ankyrin repeat and SOCS boxcontaining 7

intracellular signaling

214081_at

PLXDC1

2.759

plexin domain containing 1

multicellular organism
development

202665_s_at

WIPF1

2.953

WAS/WASL interacting protein
family, member 1

morphology, proliferation,
endocytosis, degranulation,
cytostasis, polarization

204667_at

FOXA1

2.054

forkhead box A1

development, differentiation

206112_at

ANKRD7

2.128

intracellular signaling

211207_s_at

ACSL6

2.312

213206_at

GOSR2

2.099

214814_at
216683_at

YT521
TBCA

2.23
2.822

218925_s_at

C11orf1

5.29

ankyrin repeat domain 7
acyl-CoA synthetase long-chain
family member 6
golgi SNAP receptor complex
member 2
Splicing factor YT521-B
Tubulin-specific chaperone a
chromosome 11 open reading
frame 1

Description

Functions

centaurin, beta 2
protein phosphatase 2,
regulatory subunit B , beta
isoform
ribosomal protein L17
chromosome 13 open reading
frame 1
cystathionase (cystathionine
gamma-lyase)
phospholipid scramblase 4
myozenin 1
family with sequence similarity
105, member A
chromosome 11 open reading
frame 1
transcription factor 7-like 1 (Tcell specific, HMG-box)
KIAA0280 protein

regulation of GTPase activity
apoptosis, survival
regulation of translation
Unknown
proliferation, apoptosis
blood coagulation
Assembly
Unknown
Unknown
differentiation, survival
Unknown
proliferation, apoptosis,
differentiation,
disorganization, migration

length, proliferation
transport, fusion
Unknown
Unknown
Unknown

Table 15: Genes that are specifically regulated by TAp63γ(R298Q) mutant alone when compared
to wildtype TAp63γ
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